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Central dogma suggests that mutations in target genes is the primary cause of resistance to first and 
second-line anti-TB drugs in Mycobacterium tuberculosis. However, it was previously reported that 
approximately 5% of Rifampicin mono-resistant clinical M. tuberculosis did not harbor mutations in the 
rpoB gene. The present study hypothesized that active efflux plays a contributory role in the level of 
intrinsic resistance to different anti-TB drugs (Isoniazid, Ethionamide, Pyrazinamide, Ethambutol, 
Ofloxacin, Moxifloxacin, Ciprofloxacin, Streptomycin, Amikacin and Capreomycin in RIF mono-
resistant clinical M. tuberculosis isolates with a rpoB531 (Ser-Leu) mutation. This study aimed to define 
the role of Efflux pump inhibitors (verapamil, carbonylcyanide m-chlorophenylhydrazone and reserpine) 
in enhancing the susceptibility to different anti-TB drugs in the RIF mono-resistant clinical isolates.  
The isolates were characterized by determining the level of intrinsic resistance to structurally 
related/unrelated anti-TB drugs; determining the effect of EPIs on the level of intrinsic resistance in the 
isolates and comparing the synergistic properties of the combination of EPIs and anti-TB drugs. To 
achieve this, genetic characterization was done by PCR and DNA sequencing. Phenotyping was done by 
the MGIT 960 system EpiCenter software to determine the MICs of the different anti-TB drugs and the 
effect of verapamil and carbonylcyanide m-chlorophenylhydrazone on determined MICs. Due to inability 
to test reserpine in a MGIT, a different technique (broth microdilution) was used for the reserpine 
experiment. Additionally; fractional inhibitory concentrations (FIC) indices were calculated for each of 
these drugs. The FIC assess the anti-TB drugs/inhibitor interactions. STATISTICA Software: version 11 
was used for statistical analysis. 
Results revealed that the RIF mono-resistant isolates were sensitive at the critical concentrations of all 10 
drugs tested, with the exception of Pyrazinamide. This could be explained by the technical challenges of 
phenotypic Pyrazinamide testing. A significant growth inhibitory effect was observed between the 
combination of EPI and anti-TB drug exposure in vitro. This suggests that verapamil, carbonylcyanide m-
chlorophenylhydrazone and reserpine play a significant role in restoring the susceptibility (decrease in 
intrinsic resistance level) of the RIF mono-resistant isolates to all anti-TB drugs under investigation. 
Additionally, a synergistic effect was observed by the combination treatment of the anti-TB drugs with 
the different EPIs.  
Based on these findings, we proposed a model suggesting that efflux pumps are activated by the presence 
of anti-TB drugs. The activated pumps extrude multiple or specific anti-TB drugs out of the cell, this in 
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turn decrease the intracellular drug concentration, thereby causing resistance to various anti-TB drugs. In 
contrast, the addition of EPIs inhibits efflux pump activity, leading to an increase in the intracellular drug 
concentration and ultimate cell death. This is the first study to investigate the effect of different efflux 
pumps inhibitors on the level of intrinsic resistance to a broad spectrum of anti-TB drugs in drug resistant 
M. tuberculosis clinical isolates from different genetic backgrounds. The findings are of clinical 
significance as the combination of treatment with EPI and anti-TB drugs or use of EPIs as adjunctives 























Sentrale dogma beweer dat mutasies in teiken gene die primêre oorsaak van die weerstandheid teen anti-
TB-middels in Mycobacterium tuberculosis is. Vorige studies het getoon dat ongeveer 5% van 
Rifampisien enkelweerstandige kliniese M. tuberculosis isolate nie ‘n mutasie in die rpoB geen het nie. 
Die hipotese van die huidige studie was dat aktiewe pompe 'n bydraende rol speel in die vlak van 
intrinsieke weerstandheid teen 10 verskillende anti-TB-middels (Isoniasied, Ethionamied, Pyrazinamied, 
Ethambutol, Ofloxacin, Moxifloxacin, Siprofloksasien, Streptomisien, Amikasien and Capreomycin) in 
RIF enkelweerstandige kliniese M . tuberculosis isolate met 'n rpoB531 (Ser-Leu) mutasie. Die doel van 
hierdie studie was om die rol van uitpomp inhibeerders (verapamil, carbonylcyanide m-
chlorophenylhydrazone en reserpien) te definieer in die verbetering van die werking vir verskillende anti-
TB-middels in die RIF enkelweerstandige kliniese isolate. 
Die doelstellings van die studie was om die vlak van intrinsieke weerstandigheid teen struktureel 
verwante/onverwante anti-tuberkulose middels asook die effek van die EPIs op die vlak van intrinsieke 
weerstand in die isolate is bepaal. Verder is sinergistiese eienskappe van die kombinasie van EPIs en anti-
TB-middels ondersoek. Hierdie doelstellings is bereik deur genetiese karakterisering deur PKR en DNS 
volgorde bepaling. Fenotipering is gedoen deur gebruik te maak van MGIT 960 EpiCenter sagteware om 
die Minimum Inhibisie Konsentrasie (MIC) van die verskillende anti-TB-middels en die effek van 
verapamil en carbonylcyanide m-chlorophenylhydrazone op die MIC te bepaal. Reserpien kan nie in die 
MGIT sisteem getoets word nie, and daarom is 'n ander tegniek (mikro-verdunning) is gebruik om die 
effek van reserpien te toets. Fraksionele inhiberende konsentrasies (FIC) is bereken vir elk van hierdie 
middels die anti-TB-middels / inhibeerder interaksies te bepaal. STATISTICA v11 sagteware is gebruik 
vir alle statistiese analises. 
Resultate van hierdie studie toon dat die RIF enkelweerstandige isolate sensitief is teen kritieke 
konsentrasies van al die middels, met die uitsondering van Pyrazinamied. Weerstandigheid van 
Pyrazinamied kan wees as gevolg van welbekende tegniese probleme met die standaard fenotipiese 
pyrazinamied toets. ‘n Beduidende groei inhiberende effek is waargeneem tussen die kombinasie van EPI 
en anti-TB middel blootstelling in vitro. Dit dui daarop dat verapamil, CCCP en reserpine 'n belangrike 
rol speel in die herstel van die sensitiwiteit (afname in intrinsieke weerstand vlak) van die RIF 
enkelweerstandige isolate aan alle anti-TB-middels wat ondersoek is. Daarbenewens is 'n sinergistiese 
effek waargeneem deur die kombinasie van die verskillende anti-TB-middels en die verskillende EPIs. 
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Op grond van hierdie bevindinge het ons ‘n model voorgestel wat toon dat uitvloei pompe geaktiveer 
word deur die teenwoordigheid van anti-TB-middels en die geaktiveerde pompe dan verskeie of 
spesifieke anti-TB-middels uit die sel pomp. Dus verminder die intrasellulêre konsentrasie van die middel 
en veroorsaak daardeur weerstandigheid teen verskeie anti-TB-middels. Die byvoeging van EPIs inhibeer 
uitvloei pompe se werking en lei tot 'n toename in die intrasellulêre konsentrasie van die middels en 
uiteindelik die dood van die selle. Hierdie is die eerste studie wat die effek van verskillende uitvloei 
pompe inhibeerders op die vlak van intrinsieke weerstand teen 'n breë spektrum van anti-TB-middels in 
die middel-weerstandige kliniese isolate ondersoek. Die bevindinge kan van belangrike kliniese belang 
wees aangesien die kombinasie van behandeling met EPI en anti-TB-middels die uitkoms MDR-TB 
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Tuberculosis (TB), a deadly infectious disease caused by Mycobacterium tuberculosis remains a global 
health problem (1–3). The emergence of multidrug resistant tuberculosis (MDR-TB) and extensive drug 
resistant tuberculosis (XDR-TB) has led to an inadequate availability of more anti-tubercular (anti-TB) 
drugs and raises a worldwide threat to TB eradication (3–7, 9). MDR-TB is defined as an infection with 
M. tuberculosis bacilli resistant to first-line drugs isoniazid (INH) and rifampicin (RIF) (1) and XDR-TB 
with additional resistance to a fluoroquinolone (FQ) and one of the injectables i.e. amikacin (AMI), 
kanamycin (KANA) or capreomycin (CAP) (8). Central dogma suggests that the sole cause of resistance 
to first-line and second-line anti-TB drugs in M. tuberculosis is by evolution of spontaneous mutations in 
target genes, resulting in the selection of resistant mutants (3, 9–11) (Table 1.1). Previous studies report 
that the mutations in the specific target genes will change the structure of the target protein, thereby 
affecting the drug-target binding activity thus influencing the susceptibility to the specific drug (3, 6, 12). 
However, it was previously observed that approximately 20-30% of INH resistant clinical M. tuberculosis 
isolates, harbored no mutations, in the known target genes (13, 14). Similarly, about 5% of RIF resistant 
clinical M. tuberculosis isolates did not harbour mutations in the RIF Resistance Determining Region 
(RRDR) of the rpoB gene (3, 15). Therefore, this suggests that alternative and or additional mechanisms 
could be conferring and/or defining the drug resistance level. These mechanisms include active efflux, the 
production of drug modifying enzymes and an increase in cell wall permeability (natural resistance). This 
shows that drug resistance in M. tuberculosis is more complex than previously assumed.  
Recent studies revealed that mycobacteria might use active efflux systems such as multidrug resistant 
efflux pumps (MDR EPs) to extrude structurally/functionally related and unrelated drugs  (16–19). These 
EPs are divided into different families, based on the energy source. These families include Major 
facilitator superfamily (MFS), Small multidrug resistant family (SMR), ATP binding cassette and 
Resistant nodulation cell division (RND) (17, 18, 20, 21). Independent studies showed that the exposure 
of clinical resistant M. tuberculosis cells to various drugs (INH, RIF and Ethambutol (EMB)) resulted in 
an up-regulation of different efflux pumps (8, 22). This in turn reduced the intracellular drug 
concentration which lead to clinical inefficiency (2, 3, 23, 24). Nevertheless, further addition of 
verapamil, cyanide m-chlorophenyl hydrazone (CCCP), and reserpine resulted in inhibition of these efflux 
pumps activity in M. tuberculosis cells and an increase in susceptibility (2, 5, 6, 25–27). The same 
phenomena were revealed in an in vivo macrophage-model where it was observed that the tap-like efflux 
pump, Rv1258c, was significantly up-regulated after RIF exposure leading to drug tolerance. The 
tolerance phenotype could be reversed after the addition of the efflux pump inhibitor, verapamil (5, 28).  




Based on these findings, it is important to investigate the clinical relevance of the use of the different 
efflux pumps inhibitors (EPIs) in combination with various anti-TB drugs as treatment-shortening 
adjuncts (2, 5). These EPIs in combination with the anti-TB drugs might aid in improving the efficacy of 
the current TB treatment regimen and eradicate acquired and intrinsic resistance (20).  
Table 1.1: Classes of structurally related/unrelated anti-TB drugs and the associated drug resistant 
conferring gene mutations* 
Drugs studied  Mechanism of action Gene target Frequently mutated 
codons  




Introduces negative supercoils in 
DNA molecules  
gyrA, gyrB 94GGC, 94TAC  
Aminoglycosides 
STR,  AMI, 
CAP (polypeptide) 




Inhibits cell wall synthesis katG 315ACA 
Disrupts cell wall biosynthesis InhA inhA-15prom, inhA-17prom 
EMB Inhibits cell wall synthesis embCAB 306GTG 
PZA Disrupts plasmamembrane and 
energy metabolism 
pncA 14CGC, 103TAG, 13TTC 
*The anti-TB drugs were classified according to their mechanism of action, gene target and most frequent 
mutations through literature searches (13, 29–33). 
1.2 PROBLEM STATEMENT 
The use of additional resistance mechanisms such as active efflux, by the M. tuberculosis bacillus, 
influences the efficacy of the current anti-TB treatment regimen. Recent reports indicate the involvement 
of such mechanisms in drug resistance, subsequently playing an intricate role in defining the level of RIF 
resistance. Patients infected with a RIF resistant M. tuberculosis strain requires treatment with second-line 
anti-TB drugs which is less effective, more toxic and more expensive. Furthermore, RIF, along with INH, 
PZA and EMB is administered to patients with undetected drug resistance, for up to 2 months, prior to 
drug susceptibility testing. These patients are essentially treated, during that time period, with drugs that 




are ineffective. The prolonged treatment of these patients with drugs which is ineffective, due to 
resistance, may program the M. tuberculosis bacillus to become resistant to other frequently used second-
line drugs. Subsequently, this results in the amplification of resistance and less effective MDR-TB 
treatment regimens.  This scenario emphasizes the need for the development of new anti-TB drugs with 
novel modes of action, which is a long-term process. Alternatively, compounds that might boost the 
efficacy of the current TB treatment regimen might be of clinical importance.  
The use of EPIs as potential adjuncts to improve the efficacy of existing anti-TB drugs regimens and 
restore their susceptibility has been the topic under investigation in many studies recently. However, the 
promiscuous nature of these efflux pumps complicates the simplicity of the concept, accentuating the 
knowledge gap. It is thus important to investigate the association between the efflux mechanism, the 
inhibition of this activity by EPI and the nature of the drugs (structurally related or unrelated) extruded, 
thereby studying cross-resistance (due to efflux).  
1.3 HYPOTHESIS: 
Active efflux plays a contributory and or causal role in the level of resistance to first and second-line anti-
TB drugs in rifampicin mono-resistant clinical M. tuberculosis isolates with rpoB531 (Ser-Leu) gene 
mutation.   
1.4 OVERALL AIM: 
The aim of this study is to define the role of verapamil, CCCP and reserpine in enhancing the 
susceptibility to first- and second line anti-TB drugs in RIF mono-resistant M. tuberculosis clinical 
isolates with the same rpoB531 (Ser-Leu) mutation. 
Specific aims: 
1. To genotypically characterize the RIF mono-resistant M. tuberculosis clinical isolates with the same 
rpoB531 (Ser-Leu) mutation  
2. To determine the level of resistance (as reflected by the MIC’s) of the first-line and second-line anti-
TB drugs in these clinical isolates  
3. To determine whether the addition of EPIs (verapamil, reserpine and CCCP): 
a. Has an effect on the growth of the RIF mono-resistant clinical M. tuberculosis isolates 
b. Changes the MICs of the structurally related/unrelated anti-TB drugs (INH, ETH, EMB, OFL, 
MOXI, OFL, STR, AMI and CAP)   




4. To compare the overall synergistic properties of verapamil, reserpine and CCCP in combination with 
the first- and second-line anti-TB drugs at MIC. 
1.5 EXPERIMENTAL APPROACH:  
The RIF- resistant and sensitive clinical isolates were selected and genotypically characterized by targeted 
gene sequencing. Phenotypic characterization of these isolates included the Minimum inhibitory 
concentrations (MICs) determination of the various anti-TB drugs in the MGIT 960 system and EpiCenter 
software technology. Furthermore, using the same MGIT 960 system, the effect of the EPI’s verapamil 
and CCCP on the MICs of the anti-TB drugs was determined. Additionally, the effect of reserpine on 
mycobacterial growth and the level of resistance were determined by Broth Microdilution Method 
(BMM). Lastly, to compare synergistic properties between EPIs and anti-TB drugs fractional inhibitory 
concentrations (FICs) were calculated. STATISTICA Software: version 11 was used to show statistical 
differences of EPIs experiment results data. All the work presented in this thesis was done according to 
standard operating procedures (SOP) in the Biosafety level III (P3) under safe conditions which are 
regulated by a safety officer (Appendix A). The project was approved by the ethics committee of the 
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2.1 INTRODUCTION  
Mycobacterium tuberculosis , the causative agent of Tuberculosis (TB), was discovered by Robert Koch 
in 1882 (1, 2). The introduction of Streptomycin in 1943 to treat TB resulted in a decrease in death rates 
associated with TB disease worldwide (3). However, the concomitant emergence of drug resistance 
continues to plague TB treatment globally (4, 5). Moreover, multidrug resistant TB (MDR-TB) outbreaks 
have been described since the 1990s, emphasizing MDR-TB as a global health problem (5).  
Moreover, different classes of TB drug resistance as per WHO definitions and guidelines (6) are 
summarized below. (Table 2.1). Additionally, MDR-TB is an infection with M. tuberculosis strains 
resistant to two main first-line anti-TB drugs rifampicin (RIF) and isoniazid (INH ) (6, 7). XDR-TB is M. 
tuberculosis isolates resistant to INH and RIF (MDR-TB) in addition to one of the fluoroquinolones 
(FQs) and one of the injectables amikacin (AMI), kanamycin (KANA) and capreomycin (CAP ) (6, 7). 
Recently, a somewhat controversial new term has been introduced in the literature, namely totally drug 
resistant (TDR) TB, defined as M. tuberculosis strains resistant to anti-TB drugs in addition to those 
which define XDR-TB, thereby encompassing nearly all current anti-TB drugs (8). TDR-TB, or as 
otherwise known, therapeutically destitute strains were first identified in Italy in 2007(9). This was 
followed by reports of its emergence in  Iran in 2009 and India in 2011(10, 11).  
Resistance to anti-microbial drugs covers a wide range of biological systems (12, 13), thus making it 
difficult to prevent resistance. It is suggested that the emergence of drug resistant bacilli is primarily 
attributed to genomic mutations in drug target genes (14, 15), however other mechanisms also confer the 
resistance phenotype (7, 14, 16–21). These mechanisms include: i) prevention of activating pro-drugs 
(e.g. INH) into active drugs (6, 23, 34, 35); ii) intrinsic resistance to a given drug by decreased 
permeability of the cell  membrane (7, 23) and iii) activation of efflux pump systems, resulting in a 
decrease in the intracellular drug concentration (24). One major concern is that efflux pumps have the 
ability extrude a variety of toxic compounds out the bacterial cell. This may subsequently enable the 
bacilli to escape administered drug therapies (25, 26). During that past few years the molecular 
mechanisms underlying efflux pump activity and its phenotypic consequences has become a major focus 
in mycobacterial drug resistance studies (7, 17, 28, 29). Recently, the use of efflux pump inhibitors in 
anti-TB therapy has been demonstrated in vitro to aid in the restoration of drug susceptibility and improve 
MDR-TB treatment (19). This review aims to highlight the current understanding of efflux pump 
mediated drug resistance in mycobacteria (7, 30). In addition, literature will be reviewed on the growth 
inhibitory effect of efflux pump inhibitors either alone or in combination with other compounds.  
 




Table 2.1: Classification of drug resistant treatment regimens as per WHO definitions and guidelines (9). 











Isoniazid x x x x 
Rifampicin  x x x x 
Pyrazinamide     x 
Streptomycin    x 













Injectables  Amikacin  (x)* x x 
Kanamycin 
Capreomycin 




p-aminosalicylic acid    x 
Ethionamide  
Cycloserine** 
* means either one of the 3 injectables or one of the fluoroquinolones; ** the drug is not fully 
standardized (there have not been clinical trials to confirm the actual role of this drug in drug resistance) 
(31). 
2.2 CONTRIBUTION OF EFFLUX PUMPS SYSTEMS IN THE MULTIDRUG RESISTANCE 
PHENOTYPE 
The intrinsic resistome of mycobacteria is predominated by 2 properties: activated efflux pump and 
decreased compound/drug permeability due to the mycobacterial cell wall (7, 13, 32). Efflux pumps are 
defined as protein transporters in the plasma membrane involved in the export of toxic compounds (e.g. 
antibiotics, metabolites, antibiotic peptides and dyes etc.) through the bacterial cell envelope. This 
exportation results in a decrease in the accumulation of these compounds in the bacterial cell (27, 33). 
The M. tuberculosis genome possesses various efflux pump genes enabling the bacilli to evade the 
bactericidal or bacteriostatic effects of anti-TB drugs. Interestingly, Calgin et al. showed that expression 
levels of 15 putative multidrug efflux pump genes were the same in both MDR and drug-susceptible M. 
tuberculosis isolates (34). In contrast, resistant when compared to reference strains (H37Rv), the 
resistance isolates had high gene expression levels (34). Additionally, drugs at high concentrations can act 
as inducers of efflux pumps, resulting in increased drug efflux (33, 35). A limitation of clinical 
significance is that the over expression of efflux pump genes is regulated when the bacterium is under 




selective pressure (36). This makes the reversal of drug efflux very difficult. Currently, efflux pumps 
were also revealed to play an important role in quorum sensing which signals between bacteria and in 
biofilm formation (13, 37, 38). Therefore, it is important to extrapolate how these efflux pumps function 
during extrusion of various types of structurally unrelated drugs.    
2.3 CLASSIFICATION OF FIVE CLASSES OF BACTERIAL DRUG EFFLUX PUMPS 
Bacterial efflux pumps are categorized into five distinct superfamilies with different structural 
morphologies, substrate specificities and energy sources (39–42). These include the ATP binding cassette 
(ABC), the Major facilitator superfamily (MFS), Small multidrug resistance (SMR), Resistance-
nodulation-cell division (RND) and Multidrug and toxic compound extrusion (MATE) super families 
(130). All the families are encoded by chromosomal genes and require different energy sources (7, 36, 
41). Efflux pumps of the ABC family are generally referred to as primary transporters and utilize the extra 
energy of ATP hydrolysis to extrude drugs from the cell (33). In contrast, the MFS, SMR, RND and 
MATE superfamilies are secondary multidrug transporters (43) which use transmembrane proton or 
sodium ion electrochemical gradient to energize the export drugs out of the cell (27, 39, 41, 42).  
2.3.1 Primary transporters 
The ABC transporters constitute a large superfamily of multi-subunit permeases that transport different 
molecules (44). These permeases are dependent on ATP as energy source (41, 45). ABC transporters are 
involved in the uptake of nutrients, the secretion of toxins and antibiotics through the cell membrane, also 
functionally equivalent to the human P-glycoprotein (MDR1) associated with multidrug resistance shown 
by tumor cells (41, 46–48). Thus, the same efflux mechanism is used to transfer a variety of substrates 
across the extra and intracellular membranes (48–50). The ABC transporters consists of two membrane-
spanning domains (MSDs) and two nucleotide-binding domains (NBDs) that carry signature motifs 
engaged in ATP binding (41, 42, 51). These transporters can be classified as importers (when they serve 
to import molecules from the extracellular to the intracellular environment) and as exporters (when 
involved in drugs export from cytoplasm to the extracellular environment) (7, 51, 52). Surprisingly, only 
a few bacterial ABC transporters have been shown to be involved in multiple drug transport (41) (Table 
2.2). In the sequenced M. tuberculosis H37Rv genome, the genes which encode ABC transporters 
constitute for about 2.5% of the entire genome content (7, 18, 41, 44, 48, 53).  
A limited number of ABC transporters have been shown to be associated with drug resistance in M. 
tuberculosis.  However, currently it has been reported that some ABC transporters are involved with 
reduced susceptibilities of MDR-TB clinical isolates to different antibiotics (2, 4, 18, 34). Such examples 
include M. tuberculosis Rv2686c-Rv2687c-Rv2688c operon encoding an ABC transporter accountable 




for FQs efflux when overexpressed from a multicopy plasmid (41, 48). Susceptibility to FQs was 
subsequently restored with the addition of efflux pump inhibitors, carbonyl cyanide m-
chlorophenylhydrazone (CCCP), verapamil and reserpine (54). Furthermore, in Pang et al. study, the 
transcriptional level of Rv0933 was significantly upregulated in RIF mono-resistant strains (55). 
Additionally, it was shown that exposure of laboratory generated M. smegmatis mutants, resistant to 
ciprofloxacin (CIP), resulted in significant upregulation of the pstB gene encoding a putative nucleotide-
binding subunit of the ABC transporter family. The authors concluded that this observation was primarily 
due to active efflux of CIP (6, 41).  Moreover, currently it was demonstrated that the 3.1- and 5.4-fold 
over-expression of Rv1217c and Rv1218c (ABC transporters) at transcriptional level resulted in an 
increased MIC of RIF (OR = 1.01 of Rv1217c and 1.23 of Rv1218c; including INH (OR = 1.17)(56). It 
has also been shown that the exposure of a clinical isolate of M. tuberculosis to RIF lead to 
overexpression of ABC transporter pstB and upregulation of other putative efflux pumps (Rv2136c and 
Rv1819c) by quantitative real-time PCR analysis (7, 33, 57–60). This suggests that efflux plays a role in 
RIF resistance in M. tuberculosis (7) regardless that 95% of clinical RIF resistance strains harbour 
mutations in the RIF resistance-determining region (38). M. tuberculosis exposure to some drugs used in 
the treatment of TB has been shown to upregulate efflux pump genes e.g. STR and EMB upregulates the 
ABC transporter genes drrAB in M. smegmatis which are also responsible for aminoglycoside-related 
efflux (Table 2.2). Importantly, the addition of the efflux pump inhibitors reserpine and verapamil 
restored susceptibility to some of the above compounds (7, 18). 
2.3.2 Secondary drug transporters  
The secondary transporters can be sub-divided into distinct families of transport proteins that include the 
MFS, RND, SMR and MATE superfamilies encoded by chromosomal genes (35, 61–63). Each 
superfamily is characterized by the defined spectrum of antibiotic categories recognized (27, 39, 42). A 
current study by Dinesh et al. (64) demonstrated the involvement of Rv1258c and Rv0849 (MFS), 
Rv1218c (ABC) and Rv3065 (SMR) efflux pumps in intrinsic resistance to different peptidoglycan 
synthesis inhibitors (PSI) in M. tuberculosis (64) by gene knockout. In addition, they compared in vitro 
activities of the selected drugs (vancomycin, penicillin, meropenem and ceftriaxone) on wild-type (WT) 
M. tuberculosis and the efflux pumps knockout mutants. Interestingly, the PSI showed high potency for 
the knockout mutants with uniform 4- fold (0.5 µg/ml) drop in their MICs (64). 
MFS are distributed in both gram-positive and negative bacteria (42, 65) and play a role in regulatory 
control by which their efflux mechanism is induced by the compound/drug that it exports (7, 63, 66, 67). 
Bioinformatics analysis indicate that the genome of H37Rv M. tuberculosis consists of 16 open reading 




frames encoding putative MFS superfamily efflux pumps (41, 53, 68) (Table 2.2). Examples include the 
Rv1634 protein transporter which is associated with FQ transport in M. tuberculosis (41, 68). This was 
shown after cloning Rv1634 into different vectors and which resulted in a 2 to 4 fold increase (0.12 to 
0.48 µg/ml) in the minimum inhibitory concentration (MIC) of CIP and norfloxacin in M. smegmatis. 
Contradictory studies exist regarding the effect of expression of the MFS transporter, LfrA, in FQ efflux 
and subsequent susceptibility in M. smegmatis (41, 69). The transcriptional regulator, lfrR, negatively 
regulates the expression of lfrA (70). Studies showed that the deletion of the lfrR gene resulted in an 
increase of lfrA expression. Consequently, the MIC’s for CIP, norfloxacin and ethidium bromide 
increased by 4 to 16 fold in M.smegmatis (41, 70). No homolog of the lfrA gene exist in the M. 
tuberculosis genome (41, 68). Moreover, it was revealed in Pang et al. study that increased transcriptional 
level of Rv0783 and Rv2936 confers resistance to RIF in RIF mono-resistant M. tuberculosis strains (55). 
RND superfamily transporters are known to be restricted to mycobacteria and are characterized by 12 
transmembrane spans, thereby known as “mycobacterial membrane proteins” (mmpl). Bioinformatics 
analysis of the whole genome of M. tuberculosis H37Rv revealed 15 genes encoding for putative 
transmembrane proteins belonging to the RND superfamily (Table 2.2) (53). These transmembrane 
proteins elicit an identical structural sequence which play a role in regulatory control and extrude a 
variety of different compounds. Efflux depends on gene induction by the compound that they export (41), 
whereas their functionality depends on the presence and structural orientation of the outer membrane 
canal protein (OMP) and membrane fusion protein (MFP) to pump drugs out of the cell (36, 71, 72). 
These two proteins work in conjunction, allowing the bacterium to transport compounds through both cell 
membranes straight into the external medium (36, 41, 65). This mechanism of action is best described in 
Escherichia coli by the AcrAB/TolC drug efflux pump. The AcrAB (MFP) structural system elicits a 
broad spectrum of substrate specificity, thus allowing export of a variety of drugs out of the cell via TolC 
(OMP analogue/orthologue) (41, 73, 74). It has been shown that the MmpL7 protein extrudes INH in M. 
smegmatis (26) thus suggesting that overexpression of mmpL7 in M. tuberculosis result in low-level INH 
resistance (26, 75). Additionally screening of genomic libraries and whole genome sequencing revealed 
that 1, 5-diarylpyrrole derivative (BM212) was active against MDR-TB clinical isolates. Furthermore 
when mapped BM212 to the MmpL3 protein; they found that all BM212 mutants which were 
characterized had mutations in the mmpL3 gene (76) (Table 2.2).  
SMR superfamily is part of the prokaryotic homo-oligomeric/hetero-oligomeric transport systems (41). 
These proteins are characteristically 100-120 amino acids in length with 4 membrane-spanning helices. In 
M. tuberculosis, only one protein (Mmr, Rv3065) of this superfamily has been identified by inserting the 
gene into a multicopy plasmid (Table 2.2). This resulted in a decrease in susceptibility of M. smegmatis to 




ethidium bromide, erythromycin and acriflavine (39, 41, 77, 78). It was also reported that the deletion of 
the mmr homologue in M. smegmatis, increased the susceptibility to cationic dyes and the FQs yet it had 
no effect on the susceptibility to erythromycin (41, 70).  
MATE superfamily transport proteins are the transporters with the least understood function (79, 80), due 
to their lack of sequence identity to the other 4 known families. This family is divided into 3 large 
subfamilies made up of 14 smaller groups of which only 3 consists of bacterial MATEs which are either 
NA+ or H+ antiporters (63, 79, 80). It is suggested that NorM of Vibrio parahaemolyticus putative protein 
belonging to MATE superfamily is a multidrug efflux system that extrude norfloxacin, CIP and 
structurally unrelated compounds kanamycin, streptomycin (25, 27, 79–82). This exporter was identified 
by phylogenic studies of more than 70 transport proteins families’ from Vibrio parahaemolyticus, Vibrio 
haemophilus and Bacillus species (79, 83). However more research is needed to investigate the function 
on NorM in mycobacteria as no evidence exists of NorM’s function in these bacteria. MATE transporters 
also export similar drugs transported by RND pumps. However, only few drugs exported by MATE 
















Table 2.2: Putative mycobacterial efflux pumps and genes that might be associated with drug 










































MFS Rv2846/EfpA Multiple drugs  Drug export (7, 41, 42, 53, 70, 
84) 
Rv0849  Multiple drugs Drug export (43, 68) 
Rv1410/p-55 Aminoglycosides & tetracyclines Drug export (33, 41, 85) 
 
Rv1634 FQs unknown (7, 41, 53, 68, 70) 
 
Rv1258/Tap Aminoglycosides & tetracyclines Drug export (16, 33, 41, 60) 
LfrA FQs unknown (41, 69) 
 
Rv0783 RIF Transcriptional regulation (29–33, 55) 
Rv2936 RIF Transcriptional regulation (29–33, 55) 
SMR 
 
Rv3065/mmr Erythromycin & ethidium 
bromide 
Export of multi drugs (7, 33, 41, 55, 77) 
 
emrB undetermined Efflux of multiple-drugs (7, 53, 77) 
Regulatory 
Protein 
whiB7 RIF Transcriptional regulation (32, 58)  
RND 
 
mmpL-7, mmpL3 INH, RIF Export of antibiotic multicopy 
plasmid 













ABC PstB (mtp1) FQs (specifically) CIP Overexpression in CIP-resistant 
mutant & import of inorganic 
phosphate 
(7, 9, 17, 23, 42, 
69) 
ddrAB Streptomycin, ethambutol, 
tetracycline, norfloxacin & 
erythromycin 
unknown (18, 33, 41) 
RV2686c-2687c-
2688c 
FQs Drug export (7, 33, 41, 44, 48, 
53) 
Rv1218c Multiple drugs  unknown (43, 86) 
R1217c RIF, INH Drug export (44, 55) 
Rv0933 RIF Transcriptional regulation (55, 87, 88)  




2.4. DIFFERENT EFFLUX PUMP INHIBITORS’ EFFECT ON MYCOBACTERIAL GROWTH 
The emergence of MDR- and XDR-TB has increased the complexity of the TB treatment regimen. 
Furthermore, it has emphasized the urgency in drug development and accelerated progress in new drug 
regimen development pipelines to control TB disease and transmission (89). Recently, efflux pump 
inhibitors (EPIs) have been described as putative new drug compounds as they have the ability to restore 
susceptibility to antibiotics by blocking the activity of efflux pumps (25, 27). There are different types of 
efflux pumps inhibitors which include synthetic analogues and those derived from natural sources.  
2.4.1 Proton-motive force and Ca
2+
 channel blockers  
The proton motive force and Calcium channel blockers inhibit efflux pump activity by proton pump 
interaction and reduction in the trans-membrane potential (42, 90–92). These include carbonylcyanide m-
chlorophenylhydrazone (CCCP) (Figure 2.1A), dinitrophenol (DNP) (Figure 2.1B), valinomycin (Figure 
2.1C), verapamil (Figure 2.1D) and phenothiazines (Figure 2.1E) (42, 48, 92–96). In vitro and molecular 
based research has shown that these compounds mainly inhibit the activity of efflux pumps belonging to 
the MFS superfamily (97, 98), with the exclusion of verapamil which inhibit the activity of the ABC 
superfamily. 
 
Figure 2.1: Chemical Structures of efflux pump inhibitors synthesised chemically. A) CCCP; B) DNP; 
C)Valinomycin; D) Verapamil; E) Phenothiazines (42, 48, 92–96). 
 




2.4.1.1CCCP and DNP  
CCCP and DNP (Figure 2.1A and 2.1B respectively) disperse the membrane proton-motive force by 
modification of the trans-membrane electrochemical potential which results in cell death (27, 42, 99, 
100). These compounds are rarely used commercially because of their toxic properties (101, 102). 
Additionally, these compounds are ionophores that act as chemical inhibitors of oxidative 
phosphorylation which in return inhibit the activity of ATP synthase (103).  
In a recent in vitro study, it was observed that the addition of CCCP and DNP to ofloxacin resistant M. 
tuberculosis clinical strains with gyrA mutations resulted in a 2- to 8- fold decrease in the ofloxacin MIC. 
This therefore suggests that the level of ofloxacin resistance was increased by an efflux mechanism (98, 
104). In addition, the same phenomena was reported in Gupta et al. study, the presence of CCCP and 
verapamil reversed resistance to RIF, INH, STR and OFL in M. tuberculosis isolates (33, 98). Further 
evidence to support CCCP as an effective efflux pump inhibitor includes recombinant M. tuberculosis 
H37Ra strains overexpressing Rv2459 (jefA), which resulted in an increase in the MIC of INH and 
ethambutol (EMB). The subsequent addition of CCCP to the cells resulted in a decrease in the resistance 
INH resistance (105, 106). Moreover, it was currently demonstrated that the overexpression of mmr 
(Rv3065) resulted in increased INH MIC (from 0.25 to 4 µg/ml) and decreased susceptibility to ethidium 
bromide, erythromycin and acriflavine (78). Furthermore, the addition of efflux pump inhibitors CCCP 
and verapamil was able to restore the decreased susceptibility (78). 
P55 is a tap-like MFS multidrug efflux pump (Table 2.2) that confers low-level resistance to a broad 
range of compounds (33, 85, 107). Recent studies provided evidence of the ability of CCCP and DNP to 
inhibit P55-defined drug resistance (16, 93, 108, 109). Another study also illustrated that treating M. 
tuberculosis and M. bovis BCG wild type strains with 3H-enconazole + CCCP, inhibited MmpS5-MmpL5 
efflux pumps. Additionally, that resulted in a rapid enconazole’s accumulation increase in E3 and K7 
mutant strains to the same levels as the wild-type strains (109, 110). Therefore it is clear that the 
inhibitory effect of CCCP and DNP might lead to a decrease in drug resistance and thus improving 
current TB treatment. However due to their toxicity, more novel research methods are needed in order to 
validate these findings in vivo.  
2.4.1.2. Valinomycin 
Valinomycin (Figure 2.1C) is an inhibitory compound which depletes the electrochemical gradient 
generated by potassium ions (K+) (27, 42, 99, 100). It is commercially known as dodecadepsipeptide that 
is extracted the Streptomyces species (111). Valinomycin has a high selectivity for K+ over Na+ within the 




cell membrane. It is suggested to be a potassium-specific transporter that facilitate the movement of K+ 
through lipid membranes “down” an electrochemical potential gradient (111–113). 
Limited reports exist to support valinomycin as an inhibitor of mycobacterial efflux pump activity. One of 
such reports provides evidence of valinomycin inhibiting P55-determined drug resistance in M. 
tuberculosis which prevents drug entry, thus proposing the active export of the compound as energy 
source using the transmembrane proton and electrochemical gradients (107, 109). Additionally, 
microarray analysis of M. tuberculosis strains treated with valinomycin showed a significant decrease of 
p27 and p55 expression levels (107, 109). The treatment of naturally PZA resistant M. smegmatis  with 
valinomycin showed an increase in the accumulation of pyrazinoic acid at neutral pH in M. tuberculosis 
(114, 115), illustrating the effect of efflux activity on the natural resistant PZA phenotype in these cells.  
2.4.1.3. Verapamil  
The Ca2+ channel blocker Verapamil (Figure 2.1D) belongs to phenylalkylamines prototype class. 
Commercially verapamil is used to treat various disorders including angina pectoris, hypertension and 
cardiac arrhythmia, headaches and migraines (109, 116–118). Verapamil acts by inhibiting vesicular 
monoamine transporters and P-glycoprotein in mammalian cells (109, 119). In prokaryotes, it inhibits 
ATP-dependent multidrug transporters and MDR pumps of parasites (39, 42, 99, 120). Interestingly, 
reports also illustrate that this type of inhibitor interferes with the generation of the proton-motive force 
(121). To date, numerous studies showed that verapamil has a significant inhibitory effect on 
mycobacterial efflux pump activity (95, 96, 122).  
Additionally, these studies demonstrate that verapamil inhibits active efflux of ethidium bromide in M. 
avium and M. tuberculosis strains (120, 121, and 150). Furthermore, macrolide resistance in clinical M. 
avium complex strains could also be reversed with the addition of verapamil  (95, 96, 109). Further 
support for the restoration of susceptibility comes from a recent study which showed that induced 
induction of INH resistance in M. tuberculosis strains could be reversed with the addition of verapamil to 
these cultures (123). Similarly, a recent in vitro study demonstrate that RIF resistance in mono-resistant 
and MDR M. tuberculosis strains could be reversed with the addition of verapamil. Furthermore, RIF 
induced OFL resistance was reversed with the addition of verapamil (30).  
Recently, Adams et al. showed that inhibition of mycobacterial efflux pumps with verapamil reduced 
macrophage-induced tolerance by 2-fold in a M. marinum-infected zebrafish larval model (124). In 
addition, Gupta et al. revealed that addition of verapamil to standard TB chemotherapy accelerated the 
bacterial clearance close to sterilization and lower relapse rates (4 months treatment) in a mouse model 
infected with M. tuberculosis(124, 125). Therefore, the latter studies suggest the use of efflux pumps 




inhibitors as adjunctives drugs which might significantly enhance potency of current anti-TB therapy. The 
potential clinical implication of using verapamil to restore susceptibility was demonstrated in a mouse 
infection model where treated of an MDR-TB infection with first-line TB drugs and verapamil, resulted in 
a significant decrease in the bacillary load (30, 98). However, the clinical use of verapamil in high 
concentrations is not advised due to adverse effects, such as headaches, swollen hands and legs, appetite 
loss, blurred vision, stomach pain, fever, flu-like symptoms, heartburn, constipation and nausea, despite 
these limitations, attention has been drawn to the potential use as efflux inhibitors to rejuvenate the 
efficacy of failing treatment regimens. 
2.4.1.4 Phenothiazines 
Phenothiazine (Figure 2.1E) is a yellow tricylic compound that is a substituent in various antipsychotic 
and antihistaminic drugs. Phenothiazine has derivatives widely used as drugs commercially including 
chlorpromazine, piperidine and thioridazine. This compounds are well known for its in vitro and in vivo 
antimycobacterial activity (109, 126–128). Phenothiazines are potential inhibitors of K+ transport with the 
ability to reverse the MDR phenotype. They also inhibits the proton motive-force dependent pumps by 
interaction through reduction in the trans-membrane potential (42, 102, 129, 130). Due to the emergence 
of more MDR-TB cases, it is suggested that phenothiazines have potential for the treatment of 
tuberculosis (131, 132). 
It is speculated that thioridazine has in vitro, in vivo and ex vivo activity against susceptible and resistant 
M. tuberculosis strains (127). Recently, it was demonstrated in an ex vivo experiment that thioridazine 
enhances the intracellular killing of phagocytised M. tuberculosis with a higher transport inhibition (126, 
128, 132, 133). Furthermore, it was also shown that both thioridazine and chloromazine inhibits ethidium 
bromide efflux in M. smegmatis and Mycobacterium avium complex (MAC) ( 95, 96, 124, 128, 129). 
Moreover, thioridazine reduced clarithyromycin resistance and elicited an effect on INH resistance in M. 
tuberculosis complex (121). More research is required to determine phenothiazine’s ability to inhibit 
efflux in mycobacteria, as it is shown that these compounds have only a limited inhibitory effect in vitro 
(121, 123). It is suggested that improving phenothiazine basic structure might make this compound more 
effective in vitro (109). 
2.4.2 Inhibitors from natural (plants) sources 
Alkaloids inhibit multidrug transporters and act as potential targets to help improve TB therapy. These 
include: 1. the plant alkaloid reserpine (Figure 2.2A) 2. Piperine, trans-trans isomer of 1-piperoyl-piperine 
from the Piperraceae family (Figure 2.2B) and 3. Berberine from the Berberis family (Figure 2.2C) (134–




137). Basic molecular and clinical research is required on these compounds as no data exists that could 
elucidate their interaction in vitro and in vivo. 
 
Figure 2.2: Chemical structures of efflux pump inhibitors derived from natural resources. A) Reserpine; 
B) Piperine; C) Berberine (134–137). 
2.4.2.1. Reserpine 
Reserpine (Figure 2.2A) is a naturally occurring compound isolated from the roots of Rauwolfia 
vomitoria Afz (42, 138). It is used commercially to treat wild hypertension, reduces blood pressure and 
has been shown in randomized controlled trials to reduce mortality of persons with diseases stated above 
(139). Furthermore, it irreversibly blocks the uptake (and storage) of dopamine into synaptic vesicles by 
inhibiting the vesicular monoamine transporters (140). Reserpine is also used to treat psychotic disease, 
but its use is restrained due to adverse effects it results in. These include nausea depression and nasal 
congestion. However, despite its property to act as carcinogen, it is still considered essential and as a 
promising efflux inhibitor (109, 141). Literature reports that it acts as drug potentiator by interacting 
directly with amino acids characteristic of some efflux proteins. One example is the Bmr protein 
responsible for tetracycline efflux. It is also reported that the addition of reserpine resulted in 4-fold MIC 
reduction to tetracycline in B. subtilis (137, 142, 143). Moreover, NorA-conferred resistance was fully 
reversed by reserpine, thus resulting in suppression of MDR transporters (144) in Staphylococcus aureus 
responsible for a decrease in FQs susceptibility (137).  
Recent literature supports evidence of reserpine as an inhibitor in mycobacterial efflux activity (26, 145). 
It was observed that the addition of reserpine to M. smegmatis with high level of INH resistance 
stimulated by overexpression of the M. tuberculosis mmpL7 gene (Table 2.2) resulting in a decrease of the 
level of INH resistance (19, 26, 145). Furthermore, it was also shown that reserpine inhibited the efflux 
pump responsible for pumping out active form of pyrazinamide (PZA); that is pyrazinoic acid (POA) in 




M. tuberculosis, thereby increasing susceptibility to pyrazinamide (PZA) (19, 109, 115, 146). Numerous 
studies showed that reserpine increase sensitivity to both INH and ethidium bromide in M. bovis BCG and 
decrease isoniazid efflux in M. tuberculosis (109, 147, 148). Reserpine has also been shown to restore 
susceptibility to ofloxacin (OFL) from 53 to 81% in 15 MDR-TB isolates tested (30). Recent studies, 
identified the presence of antioxidant and antimycobacterial activities in reserpine which could be of 
value in inhibiting M. tuberculosis efflux (148, 149). 
2.4.2.2. Piperine  
Piperine (Figure 2.2B) is present in black pepper and isolated from Piper nigrum sp. (150) . It was used in 
ancient times in some forms of traditional medicines. Piperine is a drug potentiator that inhibits the 
human P-glycoprotein (135, 150), particular cytochrome P450-mediated pathways and phase II reactions 
in animal models (135, 151, 152). Commercially, it inhibits enzymes important in drug metabolism, 
transport of metabolites and xenobiotics. At the same time, it subsequently increases the bioavailability of 
various compounds and alters the effectiveness of some medications (134, 135, 150). Studies done on 
piperine and piperidine, suggests its inhibitory action against bacterial efflux pumps (132, 135, 150, 153), 
including its role towards mycobacterial efflux pump activity (136). Furthermore studies have 
demonstrated the efficacy of piperine as potent inhibitor in NorA-overexpressing S.aureus strain 1199B, 
whereby the MIC of the ciprofloxacin-resistant was reduced 2-fold reduction with the addition of piperine 
(154). 
A study demonstrated inhibitory effect of piperine on the putative multidrug efflux pump in M. 
tuberculosis, Rv1258c (136). In that study the expression level of Rv1258c was assessed after treating M. 
tuberculosis H37Rv, clinical and lab-generated RIF resistant mutants, with a combination of RIF and 
piperine. After treatment, the investigators observed synergy between the piperine and RIF resulting in a 
reduction in the RIF MIC by 4- to 8-fold (lower than 2 mg/L). Gene expression analysis of Rv1258c 
revealed a 3.6-fold increase on the transcript level of R1258c conferred by RIF in RIF-resistant M. 
tuberculosis. Additionally combination treatment of RIF and piperine could restore the RIF MIC 
phenotypically to its wild type (57, 136). Additionally it was observed from a modulation assay in M. 
smegmatis that piperine decreased the MIC of ethidium bromide by 4-fold (155). This suggests that 
piperine can inhibit mycobacterial efflux pumps. 
2.4.2.3. Berberine 
Berberine (Figure 2.2C) is isolated from Berberis fremontii and is a nucleic acid-binding isoquinolone 
alkaloid with broad spectrum therapeutic properties (156). Studies on Biberine were mainly focused on its 




beneficial effects to the cardiovascular system (58), its anti-flammatory properties (157) and its ability to 
suppress different tumour cells growth in cancer (158). It is used to treat neuro-inflammation-associated 
disorders (157). This compound has been shown to be an inhibitor of multidrug resistant pumps. It 
inhibits growth of S. aureus in vitro when used in combination with methoxyhydnocarpin. (159). 
Although it has been suggested previously that berberine has weak antibacterial activity alone, it was 
shown to have a synergic effect when used in combination with other compounds such as 5’-
methoxyhydnocarpin-D, norfloxacin and other drugs which are NorA substrates in mycobacteria (137, 
159). However, limited data exist of the significance of this compound in mycobacterial resistance 
studies. 
2.5: NOVEL MYCOBACTERIAL GROWTH INHIBITORY COMPOUNDS 
The focus of recent research has been geared towards the design of novel growth inhibitory compounds. 
These include drug candidates such as Farnesol, PA-824, OPC-67683, TMC 207, PNU-100480, SQ109 
and new chemical entities which include IFN55, IFN271, IFN240 (92, 109, 160, 161). Studies report the 
growth inhibitory effect of these compounds either alone or in combination with already existing drugs to 
improve TB treatment (160, 162). Some of these novel compounds show significant growth inhibition 
properties against M. tuberculosis and therefore could potentially aid in the TB treatment regimen (163–
170). 
2.5.1 TMC207  
TMC207 is a novel diaryquinolone anti- TB drug candidate with bactericidal and sterilizing activity 
against drug-susceptible and drug-resistant M. tuberculosis in vitro (164). This drug has advanced to 
phase II clinical trials, for instance an early bactericidal activity (EBA) study of different TMC207 doses 
performed on 75 smear-positive TB patients infected with drug-susceptible M. tuberculosis stains (164). 
This study showed potent bactericidal activity after 4 days after the start of treatment. Moreover TMC207 
inhibits the activity of ATP synthase, an essential enzyme for M. tuberculosis ATP synthesis (164, 165, 
169–172). It has an MIC ranging from 0.030 to 0.120 µg/ml in M. tuberculosis (Table 2.3) (165, 170, 
171, 173). Spontaneous mutant selection and subsequent whole genome sequence analysis of the resistant 
M. tuberculosis and M. smegmatis mutants identified mutations (A63P and D32V) in the c-subunit of 
ATP synthase encoded by the atpE gene (Table 2.) (171). Mutations in atpE only partially account for the 
TMC207 resistance phenotype. No mutations in the atpE gene were observed in 38 out of 53 spontaneous 
mutants (168, 209). However, polymorphisms observed in c protein of ATP synthase did not influence 
the resistance phenotype (173). Some studies reported that TMC207 has a potent early and late bacterial 
activity, good pharmacokinetic and pharmacodynamic properties with a long half life, no effective 




toxicity in mouse and preliminary human testing (165, 167, 169, 171). Studies demonstrate synergistic 
activity of TMC207 with SQ109, which showed a 4-fold to 8-fold TMC207 MIC decrease for M. 
tuberculosis H37Rv (179).  
Interestingly in some studies (210), it was observed that TMC207 still exert significant bactericidal 
activity even with a 50% plasma concentrations reduction when exposed to RIF, thus suggesting low drug 
interaction relevance and potency of TMC207 (169). Moreover, an additive effect was observed with the 
treatment of the combination of RIF and TMC207 (179). In addition a significant synergistic effect is 
observed when PZA and TMC207 are combined (154, 155, 159, 199). This supports the findings of 
previous studies that demonstrated the strong bactericidal activity of TMC207 combined with first- or 
second-line anti-TB drugs (Table 2.3) (164, 165, 169, 174). Mice treated with the combination of 
TMC207 and PZA showed a significant decrease in lesions than those treated with RIF, INH or 
moxifloxacin (MOXI) alone (164, 174), moreover the colony forming units (CFU) decreased significantly 
in mice treated with the PZA-TMC207 combination than in mice treated with either TMC207 or PZA 
alone. Additionally more synergistic interactions included the following 3 drug combination, TMC207-
INH-PZA, TMC207-RIF-PZA; TMC207-MOXI-PZA and PNU-100480 TMC207 (179, 211). This data 
indicates TMC207’s clinical significance in TB treatment.  
2.5.2 SQ109 
SQ109 is a novel inhibitory compound discovered from a library based on the 1,2 ethylene diamide 
structure of EMB (212). SQ109 is less toxic and exhibit high potency against replicating M. tuberculosis 
(212). It has an MIC ranging from 0.16 µg/ml to 0.64 µg/ml in M. tuberculosis (Table 2.3) (164, 165, 
177). Early clinical trial data mark it as a compound that could contribute significantly in susceptible and 
MDR-TB treatment and in addition was shown to have a significant activity against intracellular bacilli 
treated during first 2 months of intensive phase therapy (213). SQ109 disrupts cell wall synthesis by 
interfering with the incorporation of mycolic acids into the cell wall core of M. tuberculosis (169, 176). 
The target of SQ109 is mmpL3 (Table 2.3), a mycolic acid transporter required for the incorporation of 
mycolic acid into the M. tuberculosis cell wall (164, 180). Numerous studies provide evidence of 
synergistic properties of SQ109 in combination with anti-TB drugs used in the current TB treatment 
regimen and other inhibitory compounds (Table 2.3) (164, 165, 169, 170, 214). A significant interaction 
was observed between SQ109 and TMC207 in vitro, with a 4- to 8-fold TMC207 MIC decrease in M. 
tuberculosis H37Rv (Table 2.3) (179). Additionally antimycobacterial activity studies done in murine 
models reported similar SQ109 activity to that of INH but more potent to that of EMB (164, 178) and 
these suggests SQ109 might replace EMB in the future for susceptible M. tuberculosis strains. 




Synergy was also observed between SQ109 and RIF in M. tuberculosis, whereby RIF caused the SQ109 
MIC to be 16-fold lower than that obtained with SQ109 alone. The presence of SQ109 also resulted in a 
decrease in the MIC of RIF by 30-fold (176, 179). The synergistic activity between RIF and SQ109 
brings hope for improving TB therapy as RIF is one of the essential front-line TB drugs used as a 
surrogate marker to detect of MDR-TB (Table 2.3). Most reported studies were done in in vitro assays; 
therefore studies are needed to assess the performance of this drug in vivo. Some in vivo studies using the 
chronic mouse model of TB showed improved efficacy of first-line drug therapy combination after 4 to 8 
weeks of treatment when SQ109 (10 mg/kg) was substituted for EMB (100 mg/kg) (170, 214). Next step 
would be to test the efficacy and pharmacokinetics of this novel compound in combination with other 
antitubercular drugs in MDR-TB patients; to ensure less adverse events and toxicity which have a bad 
influence in immuno-compromised MDR-TB and TB patients.  
2.5.3. PA-824 & OPC 67683  
PA-824 and OPC-67683 are nitromidazoles. PA-824 exhibits bactericidal activity against actively 
replicating and non-replicating M. tuberculosis. PA-824 is a pro-drug that is activated by the 
mycobacterial nitroreductase Ddn, a deazaflavin F420-dependent enzyme (215). After activation, toxic 
forms of PA-824 are able to inhibit protein synthesis and cell wall lipid synthesis, resulting in cell death. 
Investigation on the modes of action of PA-824 has shown that intermediate metabolites of PA-824 act as 
intracellular nitrogen oxide donor, therefore encouraging intracellular killing of M. tuberculosis in 
anaerobic conditions (196, 216). It inhibits cell wall lipids and protein synthesis yet its target is not fully 
described up to date (164, 165, 169, 170). Its MIC range from 0.015 to 0.25 µg/ml in M. tuberculosis 
(Table 3) (165, 169, 193, 196). Early bactericidal activity (EBA) studies showed its synergistic properties 
with PZA and MOXI (217). In a (211) current study, discrepant results were obtained for PA-824, 
TMC207, PNU-100480 combinations; combinations of PNU-100480, TMC207, and SQ109 were fully 
additive, whereas those including PA-824 were less than additive or antagonistic (211, 218). It is 
speculated that the latter is due to fact that other drugs might be more “sensitive” to bacilli growth phase 
yet PA-824 action is concentration dependent (165, 169, 193, 196) including microbial culture conditions 
(219). Recent studies reports the promising efficacy of PA-824 (160, 214) without INH (169), that might 
be developed to treat latent TB in combination with MOXI (220) and no cross-resistance is observed with 
front-line anti-TB drugs (Table 2.3) (196).  
OPC-67683 is a novel inhibitory prodrug candidate with strong activity against susceptible and MDR-TB 
(164, 165, 169, 170, 197, 198). It is structurally related to PA-824 and shares the same mechanism of 
action (165, 197), however with its MIC 10 times lower than MIC of PA-824. OPC-67683 is reported to 
be free of mutagenicity to cause permanent genetic alterations and exert highly potent activity against M. 




tuberculosis and MDR-TB (197); Moreover its MIC ranges from as low as 0.006 to 0.024 µg/ml in M. 
tuberculosis (Table 2.3) (164, 165, 169, 170, 197, 198). It targets methoxy and keto-mycolic acids and 
inhibits the cell wall biosynthesis (164–167, 169, 170, 197, 198). Recent studies provide evidence of 
superior sterilizing activity of OPC-67683 in an in vitro model of drug-tolerant M. tuberculosis (169, 
221). Combination treatment of OPC-67683 (2.5 mg/kg) with RIF (5mg/kg)/PZA (100 mg/kg) showed 
significant sterilizing activity with regards to time to negativity and lung bacillary load assessment over 2 
months treatment in M. tuberculosis compared to low synergistic effect found for standard regimen RIF 
(5 mg/kg)/PZA (100mg/kg)/INH (10 mg/kg)/EMB (100 mg/kg) in mouse and murine model in vivo (164, 
165, 169, 170, 197). Moreover preliminary human studies done with PA-824 and OPC-67683 (167, 222, 
223), showed treatment with PA-824 to be more effective at following concentrations; 200 mg, 600 mg, 
1000 mg or 1200 mg all per day for 14 days (224). Thus these findings emphasize the good synergistic 
properties of these nitroimidazoles with other anti-tubercular drugs. It could possibly have clinical 
implications in shortening TB treatment, however still more tests are required with the same reproducible 
results in vitro and in vivo. 
2.5.4 SUTEZOLID & LINEZOLID  
Sutezolid is an oxazalidinones with highly potent activity against drug-susceptible and resistant M. 
tuberculosis (225). It has an MIC as low as 0.03 to 0.50 µg/ml in M. tuberculosis (Table 2.3) (164–166, 
169, 170, 185, 225). Sutezolid targets the 50S subunit of ribosomes and inhibits the protein synthesis in 
M. tuberculosis (164, 168, 170). Current studies report superior sterilizing activity of sutezolid in 
combination with the standard first-line drugs RIF, INH and PZA in murine models (164, 189, 226). This 
suggests that the duration of TB treatment could be shortened. In addition, a synergistic effect was 
observed for the sutezolid-MOXI/PZA/TMC207/SQ109 and PA-824 combination in M. tuberculosis 
(164, 170, 189). None of these novel drug compounds exhibits cross-resistance with existing TB drugs 
(Table 2.3) (164, 168). Some phase I studies have demonstrated that sutezolid is safe and well tolerated at 
all doses and shows synergy with PZA in an ex vivo whole-blood culture assay (164, 165, 170, 188, 211). 
This suggests that new regimens comprised of this drug compound might aid in treating both drug 
sensitive and resistant M. tuberculosis strains because of its synergistic effect with PZA.  
Linezolid was the first class of oxazolidinone approved for clinical use, yet its use in TB has some 
limitations due to adverse effects (227). It is a structural analogue of sutezolid with broad activity against 
mycobacteria and gram-positive bacteria (164). Linezolid has an MIC that ranges from 0.125 to 1.0 µg/ml 
in M. tuberculosis and it has a unique mechanism of action which is supported by the absence of cross-
resistance to other antibiotics (164, 165, 184, 186, 186). It inhibits the early steps of protein synthesis by 




binding to 23S RNA in the 50S ribosomal subunit (164, 168, 170, 190). Even though clinical resistance to 
linezolid has been found to be rare, a study by Richter et al reported 1.9% resistance among 210 MDR 
strains (168, 228). In vitro-selected mutants with high level resistance to linezolid (MIC = 16 – 32 mg/l) 
have been reported to have mutations a G2061T and G2576T in the 23S rRNA gene (Table 2.3) (186, 
228). Linezolid efficacy to treat MDR-TB in combination regimens was evaluated in two studies with a 
total of 11 patients. Some patients were cured after treatment (sputum conversion and culture negativity) 
when administered with doses ranging from 600 to 1200 mg/day (160, 214). However toxic side effects, 
such as peripheral and optic neuropathy were common in these patients. In addition, linezolid is used off-
label as third-line drug in combination regimens to treat MDR-TB and XDR-TB (170, 182).  
2.5.5 MOXIFLOXACIN AND GATIFLOXACIN 
Moxifloxacin (MOXI) and Gatifloxacin are fluoroquinolones (FQs), which are promising novel growth 
inhibitory compounds of M. tuberculosis for shortening TB treatment. (229, 230). MOXI is a broad-
spectrum 8-methoxy FQ with potent bactericidal activity against M. tuberculosis and has a low MIC 
ranging from 0.18 to 0.5 µg/ml (169, 170, 200, 201, 203, 230). It targets the mycobacterial topoisomerase 
II DNA gyrase and blocks the movement of replication forks and transcription complexes (Table 2.3) 
(165, 168–170, 200, 231–233). Cross-resistance was reported within the FQs group, including mutations 
in QRDR of gyrA and gyrB genes encoding the A and B subunits of DNA gyrase (53, 168, 202, 234). 
Current in vitro and mice studies provide evidence about enhanced bactericidal activity when MOXI and 
INH is administered together (169, 235–237). Furthermore it is reported that the synergistic activity of 
RIF/MOXI with PZA could result in a novel short TB treatment regimen of 2 months, followed by 4 
months of RIF/MOXI alone, then another regimen of 2 month RIF/INH and PZA followed by 4 months 
of RIF/INH (169, 238). Moreover MOXI is also synergistic when combined with PZA and TMC207 
(164). Even more important MOXI efficacy is also evident in human studies (169) hence there are a 
number of EBA studies still on-going (51). 
Gatifloxacin, has a low MIC which ranges from 0.12 to 0.25 µg/ml (169, 170, 200, 201, 203, 230). It also 
targets and blocks mycobacterial DNA gyrase, thus preventing chromosomal replication of M. 
tuberculosis (Table 2.3) (169, 233). Cross-resistance was observed and the mechanism of resistance is 
similar to that of MOXI (169, 199, 202, 204). Gatifloxacin shows synergistic activity in RIF/INH with 
combination PZA (164, 169, 205, 206, 208) in vitro and mice studies in M. tuberculosis. Moreover, 
greater bactericidal activity was observed when gatifloxacin (100 mg/kg) was combined with ethionamide 
(ETH) (75 mg/kg) and EMB (100 mg/kg) in a mice model (169, 170, 207, 239). 
 




Table 2.3: Functional properties and promising combinations of novel mycobacterial inhibitory 


















TMC207 Inhibits its proton 
pumps 
Target AtpE (ATP synthase); no cross-
resistance with Anti-TB drugs; 
mutations in the atpE gene 
 0.030 to 
0.120  










SQ109 Disrupts cell wall 
assembly and 
block efflux pump 
activity 
Target MmpL3; no cross-resistance; no 
mutations except up regulation of ahpC 
expression 
0.16 to 0.64  Synergistic with 






Linezolid Inhibits protein 
synthesis 
Target 50S subunit of ribosomes; 
unknown cross-resistance; mutations at 
G2061T and G2576T in the 23S rRNA 
gene 










Target 50S subunit of ribosomes; 
unknown cross-resistance; mutations at 
G2061T, G2576T in the 23S rRNA gene 
0.03 to 0.50  Synergistic with 
PZA; TMC207; RIF 






PA-824 Prodrug activated 
by a nitroreductase 
(Ddn): inhibits cell 
wall lipids and 
protein synthesis 
No cross-resistance; mutations in the 
Rv3547 gene 







Inhibits cell wall 
biosynthesis 
Target methoxy- and keto-mycolic 
acids; no cross-resistance; mutations in 












Target DNA gyrase and topoisomerase 
IV; cross-resistance within FQs group; 
mutations in QRDR of gyrA and gyrB 
0.18 to 0.5  Synergistic with 
TMC207 + PZA; 










Cross-resistance within FQs group: 
mutations similar to Moxifloxacin 
Range from 
0.12 to  0.25 
µg/ml 
Synergistic with  
RIF + INH + PZA; 









2.6. Concluding Remarks 
Novel resistance mechanisms such as efflux are making it difficult to pin-point weaknesses in the genome 
of M. tuberculosis for drug design, because M. tuberculosis seems to be able to evolve in such a way that 
it has become resistant to most anti-TB drugs and in certain instances it also developed a TDR phenotype. 
These challenges therefore highlight the need for new treatment regimens.  These include the use EPI’s in 
combination with already existing drugs to help increase the potency of current anti-TB drugs. Since, to 
discover and develop a new drug is a lengthy process which takes years. Potentially, it could take more 
than 10 years from discovery, efficacy studies and to clinical trials (phase I, II and III). There have been 
some promising in vitro and in vivo reports suggesting the importance of using EPI’s as treatment-
shortening adjunctives to improve TB treatment control. Additionally, recent advances haves provided 
new hope for the development of new treatment regimens which also targets efflux activity. These include 
SQ109 and TMC207 examples of drugs currently in clinical trials. Additionally, there have been 
promising reports about Q203 as a new clinical candidate for the treatment of TB. 
Moreover, the observation that the new compounds seem to be enhancing the activity of existing anti-TB 
drugs, either through synergism or additive effects as was seen in animal models and EBA studies, will 
aid in the design of efflux pump inhibitor/antibiotic combination regimens to improve TB treatment. 
Additionally, natural sources e.g. plants, can be exploited for medicinal purposes as exemplified by 
biberine, piperine and reserpine etc. However, a key aspect is the collaboration between scientists from 
different disciplines (molecular biologists, clinicians etc), to establish a good foundation for the 
progression of translational research. It is important to validate in vitro findings in an in vivo model. In 
brief, due to increasing MDR-TB transmission cases (man-made MDR-TB), eradication requires more 
than just novel drug regimens but also most significant, managed drug delivery, patient care and the 












1.  Ito Y, Mishima M. 2011. [History, current state and future perspective of tuberculosis research 
and clinical medicine]. Nihon Rinsho Jpn. J. Clin. Med. 69:1345–1350. 
2.  Murray JF. 2004. A Century of Tuberculosis. Am. J. Respir. Crit. Care Med. 169:1181–1186. 
3.  WHO W. 2012. the introduction of streptomycin in 1943 in the regimen to treat tb resulted in a 
decrease in tb death rates worldwide - Google Search. Tuberc. World Today. apps.who.int › ... › 
Medicines Policy. 
4.  Keshavjee S, Farmer PE. 2012. Tuberculosis, drug resistance, and the history of modern 
medicine. N. Engl. J. Med. 367:931–936. 
5.  Nachega JB, Chaisson RE. 2003. Tuberculosis Drug Resistance: A Global Threat. Clin. Infect. 
Dis. 36:S24–S30. 
6.  Gupta R, Espinal MA. 2003. A prioritised research agenda for DOTS-Plus for multidrug-
resistant tuberculosis (MDR-TB). WHO. INT J TUBERC LUNG DIS 7(5):410–414 © 2003 IUATLD. 
7.  Louw GE, Warren RM, Pittius NCG van, McEvoy CRE, Helden PDV, Victor TC. 2009. A 
Balancing Act: Efflux/Influx in Mycobacterial Drug Resistance. Antimicrob. Agents Chemother. 
53:3181–3189. 
8.  Holtz TH. 2007. XDR-TB in South Africa: Revised Definition. PLoS Med 4:e161. 
9.  WHO | Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on 
surveillance and response. WHO. 
10.  Velayati AA, Farnia P, Masjedi MR, Ibrahim TA, Tabarsi P, Haroun RZ, Kuan HO, 
Ghanavi J, Farnia P, Varahram M. 2009. Totally drug-resistant tuberculosis strains: evidence of 
adaptation at the cellular level. Eur. Respir. J. Off. J. Eur. Soc. Clin. Respir. Physiol. 34:1202–1203. 
11.  Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, Hoffner SE. 2009. 
Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant 
tuberculosis or totally drug-resistant strains in iran. Chest 136:420–425. 
12.  Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. 2011. Totally Drug-Resistant Tuberculosis 
in India. Clin. Infect. Dis. 




13.  Borges-Walmsley MI, McKeegan KS, Walmsley AR. 2003. Structure and function of efflux 
pumps that confer resistance to drugs. Biochem. J. 376:313–338. 
14.  Brennan PJ, Nikaido H. 1995. The envelope of mycobacteria. Annu. Rev. Biochem. 64:29–63. 
15.  Viveiros M, Leandro C, Amaral L. 2003. Mycobacterial efflux pumps and chemotherapeutic 
implications. Int. J. Antimicrob. Agents 22:274–278. 
16.  Aínsa JA, Blokpoel MCJ, Otal I, Young DB, De Smet KAL, Martín C. 1998. Molecular 
Cloning and Characterization of Tap, a Putative Multidrug Efflux Pump Present in Mycobacterium 
fortuitum  and Mycobacterium tuberculosis. J. Bacteriol. 180:5836–5843. 
17.  Bester M. 2009. Defining mechanisms that determine the levels of drug resistance in 
Mycobacterium tuberculosis. Thesis, Stellenbosch : University of Stellenbosch. 
18.  Choudhuri BS, Bhakta S, Barik R, Basu J, Kundu M, Chakrabarti P. 2002. Overexpression 
and functional characterization of an ABC (ATP-binding cassette) transporter encoded by the genes drrA 
and drrB of Mycobacterium tuberculosis. Biochem. J. 367:279. 
19.  Louw GE. 2009. Resistance to first line anti-TB drugs by gene mutation and gene modulation. 
Thesis, Stellenbosch : University of Stellenbosch. 
20.  Ramaswamy S, Musser JM. 1998. Molecular genetic basis of antimicrobial agent resistance in 
Mycobacterium tuberculosis: 1998 update. Tuber. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis. 79:3–
29. 
21.  Wright GD. 1999. Aminoglycoside-modifying enzymes. Curr. Opin. Microbiol. 2:499–503. 
22.  Heym B, Alzari PM, Honore N, Cole ST. 1995. Missense mutations in the catalase-peroxidase 
gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol. Microbiol. 
15:235–245. 
23.  Niederweis M. 2003. Mycobacterial porins – new channel proteins in unique outer membranes. 
Mol. Microbiol. 49:1167–1177. 
24.  McMurry L, Petrucci RE, Levy SB. 1980. Active efflux of tetracycline encoded by four 
genetically different tetracycline resistance determinants in Escherichia coli. Proc. Natl. Acad. Sci. U. S. 
A. 77:3974–3977. 




25.  Neyfakh AA. 2002. Mystery of multidrug transporters: the answer can be simple. Mol. 
Microbiol. 44:1123–1130. 
26.  Pasca MR, Guglierame P, De Rossi E, Zara F, Riccardi G. 2005. mmpL7 Gene of 
Mycobacterium tuberculosis Is Responsible for Isoniazid Efflux in Mycobacterium smegmatis. 
Antimicrob. Agents Chemother. 49:4775–4777. 
27.  Pagès J-M, Masi M, Barbe J. 2005. Inhibitors of efflux pumps in Gram-negative bacteria. 
Trends Mol. Med. 11:382–389. 
28.  Johnson R, Streicher EM, Louw GE, Warren RM, van Helden PD, Victor TC. 2006. Drug 
resistance in Mycobacterium tuberculosis. Curr. Issues Mol. Biol. 8:97–111. 
29.  Savjani JK, Gajjar AK, Savjani KT. 2009. Mechanisms of resistance: useful tool to design 
antibacterial agents for drug - resistant bacteria. Mini Rev. Med. Chem. 9:194–205. 
30.  Louw GE, Warren RM, Pittius NCG van, Leon R, Jimenez A, Hernandez-Pando R, 
McEvoy CRE, Grobbelaar M, Murray M, Helden PD van, Victor TC. 2011. Rifampicin Reduces 
Susceptibility to Ofloxacin in Rifampicin-resistant Mycobacterium tuberculosis through Efflux. Am. J. 
Respir. Crit. Care Med. 184:269–276. 
31.  Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, Mitchison DA, Rist N, Smelev 
NA. 1969. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity 
tests in tuberculosis control programmes. Bull. World Health Organ. 41:21–43. 
32.  Nikaido H. 2001. Preventing drug access to targets: cell surface permeability barriers and active 
efflux in bacteria. Semin. Cell Dev. Biol. 12:215–223. 
33.  Gupta AK, Chauhan DS, Srivastava K, Das R, Batra S, Mittal M, Goswami P, Singhal N, 
Sharma VD, Venkatesan K, Hasnain SE, Katoch VM. 2006. Estimation of efflux mediated multi-drug 
resistance and its correlation with expression levels of two major efflux pumps in mycobacteria. J. 
Commun. Dis. 38:246–254. 
34.  Calgin MK, Sahin F, Turegun B, Gerceker D, Atasever M, Koksal D, Karasartova D, Kiyan 
M. 2013. Expression analysis of efflux pump genes among drug-susceptible and multidrug-resistant 
Mycobacterium tuberculosis clinical isolates and reference strains. Diagn. Microbiol. Infect. Dis. 76:291–
297. 




35.  Marger MD, Saier MH Jr. 1993. A major superfamily of transmembrane facilitators that 
catalyse uniport, symport and antiport. Trends Biochem. Sci. 18:13–20. 
36.  Hasdemir U. 2007. [The role of cell wall organization and active efflux pump systems in 
multidrug resistance of bacteria]. Mikrobiyoloji Bül. 41:309–327. 
37.  Martins A, Hunyadi A, Amaral L. 2013. Mechanisms of Resistance in Bacteria: An 
Evolutionary Approach. Open Microbiol. J. 7:53–58. 
38.  Telenti A. 1998. Genetics of drug resistant tuberculosis. Thorax 53:793–797. 
39.  Li X-Z, Nikaido H. 2004. Efflux-mediated drug resistance in bacteria. Drugs 64:159–204. 
40.  Pagès J-M, Masi M, Barbe J. 2005. Inhibitors of efflux pumps in Gram-negative bacteria. 
Trends Mol. Med. 11:382–389. 
41.  Rossi ED, Aínsa JA, Riccardi G. 2006. Role of mycobacterial efflux transporters in drug 
resistance: an unresolved question. FEMS Microbiol. Rev. 30:36–52. 
42.  Zechini B, Versace I. 2009. Inhibitors of multidrug resistant efflux systems in bacteria. Recent 
Patents Anti-Infect. Drug Disc. 4:37–50. 
43.  Balganesh M, Dinesh N, Sharma S, Kuruppath S, Nair AV, Sharma U. 2012. Efflux Pumps 
of Mycobacterium tuberculosis play a significant role in anti-tuberculosis activity of potential drug 
candidates. Antimicrob. Agents Chemother. 
44.  Braibant M, Gilot P, Content J. 2000. The ATP binding cassette (ABC) transport systems of 
Mycobacterium tuberculosis. FEMS Microbiol. Rev. 24:449–467. 
45.  Schmitt L, Tampé R. 2002. Structure and mechanism of ABC transporters. Curr. Opin. Struct. 
Biol. 12:754–760. 
46.  Méndez C, Salas JA. 2001. The role of ABC transporters in antibiotic-producing organisms: 
drug secretion and resistance mechanisms. Res. Microbiol. 152:341–350. 
47.  Davidson AL, Chen J. 2004. ATP-binding cassette transporters in bacteria. Annu. Rev. 
Biochem. 73:241–268. 




48.  Pasca MR, Guglierame P, Arcesi F, Bellinzoni M, De Rossi E, Riccardi G. 2004. Rv2686c-
Rv2687c-Rv2688c, an ABC Fluoroquinolone Efflux Pump in Mycobacterium tuberculosis. Antimicrob. 
Agents Chemother. 48:3175–3178. 
49.  Dean M, Hamon Y, Chimini G. 2001. The human ATP-binding cassette (ABC) transporter 
superfamily. J. Lipid Res. 42:1007–1017. 
50.  Szabó D, Keyzer H, Kaiser HE, Molnár J. 2000. Reversal of multidrug resistance of tumor 
cells. Anticancer Res. 20:4261–4274. 
51.  Kerr ID. 2002. Structure and association of ATP-binding cassette transporter nucleotide-binding 
domains. Biochim. Biophys. Acta BBA - Biomembr. 1561:47–64. 
52.  Kerr ID, Reynolds ED, Cove JH. 2005. ABC proteins and antibiotic drug resistance: is it all 
about transport? Biochem. Soc. Trans. 33:1000. 
53.  Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, 
Gas S, Barry CE 3rd, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, 
Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, 
McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, 
Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell 
BG. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. 
Nature 393:537–544. 
54.  Bhatt K, Banerjee SK, Chakraborti PK. 2000. Evidence that phosphate specific transporter is 
amplified in a fluoroquinolone resistant Mycobacterium smegmatis. Eur. J. Biochem. FEBS 267:4028–
4032. 
55.  Pang Y, Lu J, Wang Y, Song Y, Wang S, Zhao Y. 2013. Study of the Rifampin 
Monoresistance Mechanism in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 57:893–
900. 
56.  Wang K, Pei H, Huang B, Zhu X, Zhang J, Zhou B, Zhu L, Zhang Y, Zhou F-F. 2013. The 
expression of ABC efflux pump, Rv1217c-Rv1218c, and its association with multidrug resistance of 
Mycobacterium tuberculosis in China. Curr. Microbiol. 66:222–226. 




57.  Jiang X, Zhang W, Zhang Y, Gao F, Lu C, Zhang X, Wang H. 2008. Assessment of efflux 
pump gene expression in a clinical isolate Mycobacterium tuberculosis by real-time reverse transcription 
PCR. Microb. Drug Resist. Larchmt. N 14:7–11. 
58.  Peirs P, Lefèvre P, Boarbi S, Wang X-M, Denis O, Braibant M, Pethe K, Locht C, Huygen 
K, Content J. 2005. Mycobacterium tuberculosis with disruption in genes encoding the phosphate 
binding proteins PstS1 and PstS2 is deficient in phosphate uptake and demonstrates reduced in vivo 
virulence. Infect. Immun. 73:1898–1902. 
59.  Sarin J, Aggarwal S, Chaba R, Varshney GC, Chakraborti PK. 2001. B-subunit of 
phosphate-specific transporter from Mycobacterium tuberculosis is a thermostable ATPase. J. Biol. 
Chem. 276:44590–44597. 
60.  Siddiqi N, Das R, Pathak N, Banerjee S, Ahmed N, Katoch VM, Hasnain SE. 2004. 
Mycobacterium tuberculosis isolate with a distinct genomic identity overexpresses a tap-like efflux pump. 
Infection 32:109–111. 
61.  Saier MH Jr, Tam R, Reizer A, Reizer J. 1994. Two novel families of bacterial membrane 
proteins concerned with nodulation, cell division and transport. Mol. Microbiol. 11:841–847. 
62.  Paulsen IT, Skurray RA, Tam R, Saier MH Jr, Turner RJ, Weiner JH, Goldberg EB, 
Grinius LL. 1996. The SMR family: a novel family of multidrug efflux proteins involved with the efflux 
of lipophilic drugs. Mol. Microbiol. 19:1167–1175. 
63.  Putman M, van Veen HW, Konings WN. 2000. Molecular Properties of Bacterial Multidrug 
Transporters. Microbiol. Mol. Biol. Rev. 64:672–693. 
64.  Dinesh N, Sharma S, Balganesh M. 2013. Involvement of efflux pumps in the resistance to 
peptidoglycan synthesis inhibitors in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 
57:1941–1943. 
65.  Tseng TT, Gratwick KS, Kollman J, Park D, Nies DH, Goffeau A, Saier MH Jr. 1999. The 
RND permease superfamily: an ancient, ubiquitous and diverse family that includes human disease and 
development proteins. J. Mol. Microbiol. Biotechnol. 1:107–125. 
66.  Bambeke FV, Glupczynski Y, Plésiat P, Pechère JC, Tulkens PM. 2003. Antibiotic efflux 
pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial 
therapy. J. Antimicrob. Chemother. 51:1055–1065. 




67.  Ogawa W, Koterasawa M, Kuroda T, Tsuchiya T. 2006. KmrA multidrug efflux pump from 
Klebsiella pneumoniae. Biol. Pharm. Bull. 29:550–553. 
68.  De Rossi E, Arrigo P, Bellinzoni M, Silva PAE, Martín C, Aínsa JA, Guglierame P, Riccardi 
G. 2002. The multidrug transporters belonging to major facilitator superfamily in Mycobacterium 
tuberculosis. Mol. Med. 8:714–724. 
69.  Takiff HE, Cimino M, Musso MC, Weisbrod T, Martinez R, Delgado MB, Salazar L, Bloom 
BR, Jacobs WR. 1996. Efflux pump of the proton antiporter family confers low-level fluoroquinolone 
resistance in Mycobacterium smegmatis. Proc. Natl. Acad. Sci. 93:362–366. 
70.  Li X-Z, Zhang L, Nikaido H. 2004. Efflux Pump-Mediated Intrinsic Drug Resistance in 
Mycobacterium smegmatis. Antimicrob. Agents Chemother. 48:2415–2423. 
71.  Poole K. 2005. Efflux-mediated antimicrobial resistance. J. Antimicrob. Chemother. 56:20–51. 
72.  Piddock LJV. 2006. Clinically Relevant Chromosomally Encoded Multidrug Resistance Efflux 
Pumps in Bacteria. Clin. Microbiol. Rev. 19:382–402. 
73.  Nikaido H, Zgurskaya HI. 2001. AcrAB and related multidrug efflux pumps of Escherichia 
coli. J. Mol. Microbiol. Biotechnol. 3:215–218. 
74.  Zgurskaya HI, Nikaido H. 2000. Multidrug resistance mechanisms: drug efflux across two 
membranes. Mol. Microbiol. 37:219–225. 
75.  Domenech P, Reed MB, Barry CE. 2005. Contribution of the Mycobacterium tuberculosis 
MmpL Protein Family to Virulence and Drug Resistance. Infect. Immun. 73:3492–3501. 
76.  La Rosa V, Poce G, Canseco JO, Buroni S, Pasca MR, Biava M, Raju RM, Porretta GC, 
Alfonso S, Battilocchio C, Javid B, Sorrentino F, Ioerger TR, Sacchettini JC, Manetti F, Botta M, 
De Logu A, Rubin EJ, De Rossi E. 2012. MmpL3 Is the Cellular Target of the Antitubercular Pyrrole 
Derivative BM212. Antimicrob. Agents Chemother. 56:324–331. 
77.  Rossi ED, Branzoni M, Cantoni R, Milano A, Riccardi G, Ciferri O. 1998. mmr, a 
Mycobacterium tuberculosis Gene Conferring Resistance to Small Cationic Dyes and Inhibitors. J. 
Bacteriol. 180:6068–6071. 
78.  Rodrigues L, Villellas C, Bailo R, Viveiros M, Aínsa JA. 2013. Role of the Mmr efflux pump 
in drug resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 57:751–757. 




79.  Brown MH, Paulsen IT, Skurray RA. 1999. The multidrug efflux protein NorM is a prototype 
of a new family of transporters. Mol. Microbiol. 31:394–395. 
80.  Omote H, Hiasa M, Matsumoto T, Otsuka M, Moriyama Y. 2006. The MATE proteins as 
fundamental transporters of metabolic and xenobiotic organic cations. Trends Pharmacol. Sci. 27:587–
593. 
81.  Moreira MAS, Souza EC de, Moraes CA de. 2004. Multidrug efflux systems in Gram-negative 
bacteria. Braz. J. Microbiol. 35:19–28. 
82.  Morita Y, Kodama K, Shiota S, Mine T, Kataoka A, Mizushima T, Tsuchiya T. 1998. NorM, 
a putative multidrug efflux protein, of Vibrio parahaemolyticus and its homolog in Escherichia coli. 
Antimicrob. Agents Chemother. 42:1778–1782. 
83.  Paulsen IT, Sliwinski MK, Nelissen B, Goffeau A, Saier Jr. MH. 1998. Unified inventory of 
established and putative transporters encoded within the complete genome of Saccharomyces cerevisiae. 
FEBS Lett. 430:116–125. 
84.  Doran JL, Pang Y, Mdluli KE, Moran AJ, Victor TC, Stokes RW, Mahenthiralingam E, 
Kreiswirth BN, Butt JL, Baron GS, Treit JD, Kerr VJ, Helden PDV, Roberts MC, Nano FE. 1997. 
Mycobacterium tuberculosis efpA encodes an efflux protein of the QacA transporter family. Clin. Diagn. 
Lab. Immunol. 4:23–32. 
85.  Silva PE, Bigi F, Santangelo MP, Romano MI, Martín C, Cataldi A, Aínsa JA. 2001. 
Characterization of P55, a multidrug efflux pump in Mycobacterium bovis and Mycobacterium 
tuberculosis. Antimicrob. Agents Chemother. 45:800–804. 
86.  Balganesh M, Kuruppath S, Marcel N, Sharma S, Nair A, Sharma U. 2010. Rv1218c, an 
ABC transporter of Mycobacterium tuberculosis with implications in drug discovery. Antimicrob. Agents 
Chemother. 54:5167–5172. 
87.  Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. 2002. Evaluation of a nutrient 
starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. 
Mol. Microbiol. 43:717–731. 
88.  Gamboa F, Cardona PJ, Manterola JM, Lonca J, Matas L, Padilla E, Manzano JR, Ausina 
V. 1998. Evaluation of a commercial probe assay for detection of rifampin resistance in Mycobacterium 




tuberculosis directly from respiratory and nonrespiratory clinical samples. Eur. J. Clin. Microbiol. Infect. 
Dis. Off. Publ. Eur. Soc. Clin. Microbiol. 17:189–192. 
89.  Lougheed KEA, Osborne SA, Saxty B, Whalley D, Chapman T, Bouloc N, Chugh J, Nott 
TJ, Patel D, Spivey VL, Kettleborough CA, Bryans JS, Taylor DL, Smerdon SJ, Buxton RS. 2011. 
Effective inhibitors of the essential kinase PknB and their potential as anti-mycobacterial agents. Tuberc. 
Edinb. Scotl. 91:277–286. 
90.  Aeschlimann JR, Dresser LD, Kaatz GW, Rybak MJ. 1999. Effects of NorA inhibitors on in 
vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in 
genetically related strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 43:335–340. 
91.  Aeschlimann JR, Kaatz GW, Rybak MJ. 1999. The effects of NorA inhibition on the activities 
of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus 
aureus in an in-vitro infection model. J. Antimicrob. Chemother. 44:343–349. 
92.  Van Bambeke F, Pagès J-M, Lee VJ. 2006. Inhibitors of bacterial efflux pumps as adjuvants in 
antibiotic treatments and diagnostic tools for detection of resistance by efflux. Recent Patents Anti-Infect. 
Drug Disc. 1:157–175. 
93.  Ramón-García S, Martín C, Aínsa JA, De Rossi E. 2006. Characterization of tetracycline 
resistance mediated by the efflux pump Tap from Mycobacterium fortuitum. J. Antimicrob. Chemother. 
57:252–259. 
94.  Rodrigues L, Aínsa JA, Amaral L, Viveiros M. 2011. Inhibition of drug efflux in mycobacteria 
with phenothiazines and other putative efflux inhibitors. Recent Patents Anti-Infect. Drug Disc. 6:118–
127. 
95.  Rodrigues L, Sampaio D, Couto I, Machado D, Kern WV, Amaral L, Viveiros M. 2009. The 
role of efflux pumps in macrolide resistance in Mycobacterium avium complex. Int. J. Antimicrob. Agents 
34:529–533. 
96.  Rodrigues L, Wagner D, Viveiros M, Sampaio D, Couto I, Vavra M, Kern WV, Amaral L. 
2008. Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in Mycobacterium avium 
and Mycobacterium smegmatis. J. Antimicrob. Chemother. 61:1076–1082. 




97.  Banerjee SK, Bhatt K, Rana S, Misra P, Chakraborti PK. 1996. Involvement of an efflux 
system in mediating high level of fluoroquinolone resistance in Mycobacterium smegmatis. Biochem. 
Biophys. Res. Commun. 226:362–368. 
98.  Singh M, Jadaun GPS, Ramdas, Srivastava K, Chauhan V, Mishra R, Gupta K, Nair S, 
Chauhan DS, Sharma VD, Venkatesan K, Katoch VM. 2011. Effect of efflux pump inhibitors on drug 
susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates. Indian J. Med. Res. 133:535–
540. 
99.  Mahamoud A, Chevalier J, Alibert-Franco S, Kern WV, Pagès J-M. 2007. Antibiotic efflux 
pumps in Gram-negative bacteria: the inhibitor response strategy. J. Antimicrob. Chemother. 59:1223–
1229. 
100.  Mallea M, Chevalier J, Bornet C, Eyraud A, Davin-Regli A, Bollet C, Pagès JM. 1998. Porin 
alteration and active efflux: two in vivo drug resistance strategies used by Enterobacter aerogenes. 
Microbiol. Read. Engl. 144 ( Pt 11):3003–3009. 
101.  Gásková D, Brodská B, Holoubek A, Sigler K. 1999. Factors and processes involved in 
membrane potential build-up in yeast: diS-C3(3) assay. Int. J. Biochem. Cell Biol. 31:575–584. 
102.  Molnár J, Hevér A, Fakla I, Fischer J, Ocsovski I, Aszalós A. 1997. Inhibition of the transport 
function of membrane proteins by some substituted phenothiazines in E. coli and multidrug resistant 
tumor cells. Anticancer Res. 17:481–486. 
103.  Park JW, Lee SY, Yang JY, Rho HW, Park BH, Lim SN, Kim JS, Kim HR. 1997. Effect of 
carbonyl cyanide m-chlorophenylhydrazone (CCCP) on the dimerization of lipoprotein lipase. Biochim. 
Biophys. Acta 1344:132–138. 
104.  Pitaksajjakul P, Wongwit W, Punprasit W, Eampokalap B, Peacock S, Ramasoota P. 2005. 
Mutations in the gyrA and gyrB genes of fluoroquinolone-resistant Mycobacterium tuberculosis from TB 
patients in Thailand. Southeast Asian J. Trop. Med. Public Health 36 Suppl 4:228–237. 
105.  Da Silva PEA, Von Groll A, Martin A, Palomino JC. 2011. Efflux as a mechanism for drug 
resistance in Mycobacterium tuberculosis. FEMS Immunol. Med. Microbiol. 63:1–9. 
106.  Gupta AK, Reddy VP, Lavania M, Chauhan DS, Venkatesan K, Sharma VD, Tyagi AK, 
Katoch VM. 2010. jefA (Rv2459), a drug efflux gene in Mycobacterium tuberculosis confers resistance 
to isoniazid & ethambutol. Indian J. Med. Res. 132:176–188. 




107.  Ramón-García S, Martín C, Thompson CJ, Aínsa JA. 2009. Role of the Mycobacterium 
tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth. 
Antimicrob. Agents Chemother. 53:3675–3682. 
108.  Ramón-García S, Mick V, Dainese E, Martín C, Thompson CJ, De Rossi E, Manganelli R, 
Aínsa JA. 2012. Functional and genetic characterization of the tap efflux pump in Mycobacterium bovis 
BCG. Antimicrob. Agents Chemother. 56:2074–2083. 
109.  Viveiros M, Martins M, Rodrigues L, Machado D, Couto I, Ainsa J, Amaral L. 2012. 
Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs. Expert Rev. Anti 
Infect. Ther. 10:983–998. 
110.  Milano A, Pasca MR, Provvedi R, Lucarelli AP, Manina G, Ribeiro AL de JL, Manganelli 
R, Riccardi G. 2009. Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-
MmpL5 efflux system. Tuberc. Edinb. Scotl. 89:84–90. 
111.  Rose L, Jenkins ATA. 2007. The effect of the ionophore valinomycin on biomimetic solid 
supported lipid DPPTE/EPC membranes. Bioelectrochemistry 70:387–393. 
112.  R P Daniele SKH. 1976. A potassium ionophore (valinomycin) inhibits lymphocyte proliferation 
by its effects on the cell membrane. Proc. Natl. Acad. Sci. U. S. A. 73:3599–602. 
113.  Safiulina D, Veksler V, Zharkovsky A, Kaasik A. 2006. Loss of mitochondrial membrane 
potential is associated with increase in mitochondrial volume: physiological role in neurones. J. Cell. 
Physiol. 206:347–353. 
114.  Ramos S, Schuldiner S, Kaback HR. 1976. The electrochemical gradient of protons and its 
relationship to active transport in Escherichia coli membrane vesicles. Proc. Natl. Acad. Sci. U. S. A. 
73:1892–1896. 
115.  Zhang Y, Scorpio A, Nikaido H, Sun Z. 1999. Role of Acid pH and Deficient Efflux of 
Pyrazinoic Acid in Unique Susceptibility of Mycobacterium tuberculosis to Pyrazinamide. J. Bacteriol. 
181:2044–2049. 
116.  Andersen CL, Holland IB, Jacq A. 2006. Verapamil, a Ca2+ channel inhibitor acts as a local 
anesthetic and induces the sigma E dependent extra-cytoplasmic stress response in E. coli. Biochim. 
Biophys. Acta 1758:1587–1595. 




117.  Beck E, Sieber WJ, Trejo R. 2005. Management of cluster headache. Am. Fam. Physician 
71:717–724. 
118.  McTavish D, Sorkin EM. 1989. Verapamil. An updated review of its pharmacodynamic and 
pharmacokinetic properties, and therapeutic use in hypertension. Drugs 38:19–76. 
119.  Endicott JA, Ling V. 1989. The biochemistry of P-glycoprotein-mediated multidrug resistance. 
Annu. Rev. Biochem. 58:137–171. 
120.  Poelarends GJ, Mazurkiewicz P, Konings WN. 2002. Multidrug transporters and antibiotic 
resistance in Lactococcus lactis. Biochim. Biophys. Acta 1555:1–7. 
121.  Rodrigues L, Machado D, Couto I, Amaral L, Viveiros M. 2012. Contribution of efflux 
activity to isoniazid resistance in the Mycobacterium tuberculosis complex. Infect. Genet. Evol. J. Mol. 
Epidemiol. Evol. Genet. Infect. Dis. 12:695–700. 
122.  Rodrigues LP, Iglesias D, Nicola FC, Steffens D, Valentim L, Witczak A, Zanatta G, 
Achaval M, Pranke P, Netto CA. 2012. Transplantation of mononuclear cells from human umbilical 
cord blood promotes functional recovery after traumatic spinal cord injury in Wistar rats. Braz. J. Med. 
Biol. Res. Rev. Bras. Pesqui. Médicas E Biológicas Soc. Bras. Biofísica Al 45:49–57. 
123.  Machado D, Couto I, Perdigão J, Rodrigues L, Portugal I, Baptista P, Veigas B, Amaral L, 
Viveiros M. 2012. Contribution of Efflux to the Emergence of Isoniazid and Multidrug Resistance in 
Mycobacterium tuberculosis. PLoS ONE 7:e34538. 
124.  Adams KN, Takaki K, Connolly LE, Wiedenhoft H, Winglee K, Humbert O, Edelstein PH, 
Cosma CL, Ramakrishnan L. 2011. Drug tolerance in replicating mycobacteria mediated by a 
macrophage-induced efflux mechanism. Cell 145:39–53. 
125.  Gupta S, Tyagi S, Almeida DV, Maiga MC, Ammerman NC, Bishai WR. 2013. Acceleration 
of Tuberculosis Treatment by Adjunctive Therapy with Verapamil as an Efflux Inhibitor. Am. J. Respir. 
Crit. Care Med. 
126.  Amaral L, Kristiansen JE, Abebe LS, Millett W. 1996. Inhibition of the respiration of multi-
drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial 
therapy of freshly diagnosed tuberculosis. J. Antimicrob. Chemother. 38:1049–1053. 




127.  Martins M, Schelz Z, Martins A, Molnar J, Hajös G, Riedl Z, Viveiros M, Yalcin I, Aki-
Sener E, Amaral L. 2007. In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium 
tuberculosis. Int. J. Antimicrob. Agents 29:338–340. 
128.  Ordway D, Viveiros M, Leandro C, Bettencourt R, Almeida J, Martins M, Kristiansen JE, 
Molnar J, Amaral L. 2003. Clinical Concentrations of Thioridazine Kill Intracellular Multidrug-
Resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47:917–922. 
129.  Martins M, Dastidar SG, Fanning S, Kristiansen JE, Molnar J, Pagès J-M, Schelz Z, 
Spengler G, Viveiros M, Amaral L. 2008. Potential role of non-antibiotics (helper compounds) in the 
treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect 
activities. Int. J. Antimicrob. Agents 31:198–208. 
130.  Viveiros M, Amaral L. 2001. Enhancement of antibiotic activity against poly-drug resistant 
Mycobacterium tuberculosis by phenothiazines. Int. J. Antimicrob. Agents 17:225–228. 
131.  Amaral L, Viveiros M, Kristiansen JE. 2001. Phenothiazines: potential alternatives for the 
management of antibiotic resistant infections of tuberculosis and malaria in developing countries. Trop. 
Med. Int. Health TM IH 6:1016–1022. 
132.  Amaral L, Martins M, Viveiros M. 2007. Enhanced killing of intracellular multidrug-resistant 
Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J. Antimicrob. 
Chemother. 59:1237–1246. 
133.  Martins M, Viveiros M, Amaral L. 2008. Inhibitors of Ca2+ and K+ Transport Enhance 
Intracellular Killing of M. tuberculosis by Non-killing Macrophages. In Vivo 22:69–75. 
134.  Atal CK, Dubey RK, Singh J. 1985. Biochemical basis of enhanced drug bioavailability by 
piperine: evidence that piperine is a potent inhibitor of drug metabolism. J. Pharmacol. Exp. Ther. 
232:258–262. 
135.  Khan IA, Mirza ZM, Kumar A, Verma V, Qazi GN. 2006. Piperine, a Phytochemical 
Potentiator of Ciprofloxacin against Staphylococcus aureus. Antimicrob. Agents Chemother. 50:810–812. 
136.  Sharma S, Kumar M, Sharma S, Nargotra A, Koul S, Khan IA. 2010. Piperine as an inhibitor 
of Rv1258c, a putative multidrug efflux pump of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 
65:1694–1701. 




137.  Stavri M, Piddock LJV, Gibbons S. 2007. Bacterial efflux pump inhibitors from natural 
sources. J. Antimicrob. Chemother. 59:1247–1260. 
138.  POISSON J, LE HIR A, GOUTAREL R, JANOT MM. 1954. [Isolation of reserpine from 
roots of Rauwolfia vomitoria Afz]. Comptes Rendus Hebd. Séances Académie Sci. 238:1607–1609. 
139.  1979. Five-year findings of the hypertension detection and follow-up program. I. Reduction in 
mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and 
Follow-up Program Cooperative Group. JAMA J. Am. Med. Assoc. 242:2562–2571. 
140.  Schuldiner S, Liu Y, Edwards RH. 1993. Reserpine binding to a vesicular amine transporter 
expressed in Chinese hamster ovary fibroblasts. J. Biol. Chem. 268:29–34. 
141.  Grossman E, Messerli FH, Goldbourt U. 2002. Carcinogenicity of antihypertensive therapy. 
Curr. Hypertens. Rep. 4:195–201. 
142.  Gibbons S, Udo EE. 2000. The effect of reserpine, a modulator of multidrug efflux pumps, on 
the in vitro activity of tetracycline against clinical isolates of methicillin resistant Staphylococcus aureus 
(MRSA) possessing the tet(K) determinant. Phytother. Res. PTR 14:139–140. 
143.  Neyfakh AA, Bidnenko VE, Chen LB. 1991. Efflux-mediated multidrug resistance in Bacillus 
subtilis: similarities and dissimilarities with the mammalian system. Proc. Natl. Acad. Sci. U. S. A. 
88:4781–4785. 
144.  Neyfakh AA, Borsch CM, Kaatz GW. 1993. Fluoroquinolone resistance protein NorA of 
Staphylococcus aureus is a multidrug efflux transporter. Antimicrob. Agents Chemother. 37:128–129. 
145.  Choudhuri BS, Sen S, Chakrabarti P. 1999. Isoniazid accumulation in Mycobacterium 
smegmatis is modulated by proton motive force-driven and ATP-dependent extrusion systems. Biochem. 
Biophys. Res. Commun. 256:682–684. 
146.  Zhang Y, Permar S, Sun Z. 2002. Conditions that may affect the results of susceptibility testing 
of Mycobacterium tuberculosis to pyrazinamide. J. Med. Microbiol. 51:42–49. 
147.  Colangeli R, Helb D, Sridharan S, Sun J, Varma-Basil M, Hazbón MH, Harbacheuski R, 
Megjugorac NJ, Jacobs WR Jr, Holzenburg A, Sacchettini JC, Alland D. 2005. The Mycobacterium 
tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both 
isoniazid and ethambutol. Mol. Microbiol. 55:1829–1840. 




148.  Viveiros M, Portugal I, Bettencourt R, Victor TC, Jordaan AM, Leandro C, Ordway D, 
Amaral L. 2002. Isoniazid-induced transient high-level resistance in Mycobacterium tuberculosis. 
Antimicrob. Agents Chemother. 46:2804–2810. 
149.  Begum S, Naqvi SQZ, Ahmed A, Tauseef S, Siddiqui BS. 2012. Antimycobacterial and 
antioxidant activities of reserpine and its derivatives. Nat. Prod. Res. 26:2084–2088. 
150.  Bhardwaj RK, Glaeser H, Becquemont L, Klotz U, Gupta SK, Fromm MF. 2002. Piperine, a 
major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther. 
302:645–650. 
151.  Atal CK, Zutshi U, Rao PG. 1981. Scientific evidence on the role of Ayurvedic herbals on 
bioavailability of drugs. J. Ethnopharmacol. 4:229–232. 
152.  Singh J, Dubey RK, Atal CK. 1986. Piperine-mediated inhibition of glucuronidation activity in 
isolated epithelial cells of the guinea-pig small intestine: evidence that piperine lowers the endogeneous 
UDP-glucuronic acid content. J. Pharmacol. Exp. Ther. 236:488–493. 
153.  Lee SA, Hong SS, Han XH, Hwang JS, Oh GJ, Lee KS, Lee MK, Hwang BY, Ro JS. 2005. 
Piperine from the fruits of Piper longum with inhibitory effect on monoamine oxidase and antidepressant-
like activity. Chem. Pharm. Bull. (Tokyo) 53:832–835. 
154.  Thota N, Koul S, Reddy MV, Sangwan PL, Khan IA, Kumar A, Raja AF, Andotra SS, Qazi 
GN. 2008. Citral derived amides as potent bacterial NorA efflux pump inhibitors. Bioorg. Med. Chem. 
16:6535–6543. 
155.  Jin J, Zhang J, Guo N, Feng H, Li L, Liang J, Sun K, Wu X, Wang X, Liu M, Deng X, Yu L. 
2011. The plant alkaloid piperine as a potential inhibitor of ethidium bromide efflux in Mycobacterium 
smegmatis. J. Med. Microbiol. 60:223–229. 
156.  Bhadra K, Kumar GS. 2011. Therapeutic potential of nucleic acid-binding isoquinoline 
alkaloids: binding aspects and implications for drug design. Med. Res. Rev. 31:821–862. 
157.  Kuo C-L, Chi C-W, Liu T-Y. 2004. The anti-inflammatory potential of berberine in vitro and in 
vivo. Cancer Lett. 203:127–137. 
158.  Kim JB, Yu J-H, Ko E, Lee K-W, Song AK, Park SY, Shin I, Han W, Noh DY. 2010. The 
alkaloid Berberine inhibits the growth of Anoikis-resistant MCF-7 and MDA-MB-231 breast cancer cell 
lines by inducing cell cycle arrest. Phytomedicine Int. J. Phytother. Phytopharm. 17:436–440. 




159.  Stermitz FR, Lorenz P, Tawara JN, Zenewicz LA, Lewis K. 2000. Synergy in a medicinal 
plant: antimicrobial action of berberine potentiated by 5’-methoxyhydnocarpin, a multidrug pump 
inhibitor. Proc. Natl. Acad. Sci. U. S. A. 97:1433–1437. 
160.  Jin J, Zhang J-Y, Guo N, Sheng H, Li L, Liang J-C, Wang X-L, Li Y, Liu M-Y, Wu X-P, Yu 
L. 2010. Farnesol, a potential efflux pump inhibitor in Mycobacterium smegmatis. Mol. Basel Switz. 
15:7750–7762. 
161.  Markham PN, Westhaus E, Klyachko K, Johnson ME, Neyfakh AA. 1999. Multiple Novel 
Inhibitors of the NorA Multidrug Transporter of Staphylococcus aureus. Antimicrob. Agents Chemother. 
43:2404–2408. 
162.  Marquez B. 2005. Bacterial efflux systems and efflux pumps inhibitors. Biochimie 87:1137–
1147. 
163.  Barry CE, Blanchard JS. 2010. The Chemical Biology of New Drugs in Development for 
Tuberculosis. Curr. Opin. Chem. Biol. 14:456–466. 
164.  Engohang-Ndong J. 2012. Antimycobacterial drugs currently in Phase II clinical trials and 
preclinical phase for tuberculosis treatment. Expert Opin. Investig. Drugs 21:1789–1800. 
165.  Grosset JH, Singer TG, Bishai WR. 2012. New drugs for the treatment of tuberculosis: hope 
and reality. Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis. 16:1005–1014. 
166.  Lienhardt C, Vernon A, Raviglione MC. 2010. New drugs and new regimens for the treatment 
of tuberculosis: review of the drug development pipeline and implications for national programmes. Curr. 
Opin. Pulm. Med. 16:186–193. 
167.  Sacks LV, Behrman RE. 2009. Challenges, successes and hopes in the development of novel 
TB therapeutics. Future Med. Chem. 1:749–756. 
168.  Silva PEAD, Palomino JC. 2011. Molecular basis and mechanisms of drug resistance in 
Mycobacterium tuberculosis: classical and new drugs. J. Antimicrob. Chemother. 
169.  Van den Boogaard J, Kibiki GS, Kisanga ER, Boeree MJ, Aarnoutse RE. 2009. New Drugs 
against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development. 
Antimicrob. Agents Chemother. 53:849–862. 




170.  Villemagne B, Crauste C, Flipo M, Baulard AR, Déprez B, Willand N. 2012. Tuberculosis: 
The drug development pipeline at a glance. Eur. J. Med. Chem. 51:1–16. 
171.  Andries K, Verhasselt P, Guillemont J, Göhlmann HWH, Neefs J-M, Winkler H, Gestel JV, 
Timmerman P, Zhu M, Lee E, Williams P, Chaffoy D de, Huitric E, Hoffner S, Cambau E, Truffot-
Pernot C, Lounis N, Jarlier V. 2005. A Diarylquinoline Drug Active on the ATP Synthase of 
Mycobacterium tuberculosis. Science 307:223–227. 
172.  Haagsma AC, Podasca I, Koul A, Andries K, Guillemont J, Lill H, Bald D. 2011. Probing the 
interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase. PloS One 
6:e23575. 
173.  Huitric E, Verhasselt P, Andries K, Hoffner SE. 2007. In vitro antimycobacterial spectrum of a 
diarylquinoline ATP synthase inhibitor. Antimicrob. Agents Chemother. 51:4202–4204. 
174.  Ibrahim M, Andries K, Lounis N, Chauffour A, Truffot-Pernot C, Jarlier V, Veziris N. 
2007. Synergistic Activity of R207910 Combined with Pyrazinamide against Murine Tuberculosis. 
Antimicrob. Agents Chemother. 51:1011–1015. 
175.  Rouan M-C, Lounis N, Gevers T, Dillen L, Gilissen R, Raoof A, Andries K. 2012. 
Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model 
of tuberculosis. Antimicrob. Agents Chemother. 56:1444–1451. 
176.  Chen P, Gearhart J, Protopopova M, Einck L, Nacy CA. 2006. Synergistic interactions of 
SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J. Antimicrob. Chemother. 
58:332–337. 
177.  Heifets LB, Iseman MD, Lindholm-Levy PJ. 1986. Ethambutol MICs and MBCs for 
Mycobacterium avium complex and Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 
30:927–932. 
178.  Jia L, Coward L, Gorman GS, Noker PE, Tomaszewski JE. 2005. Pharmacoproteomic effects 
of isoniazid, ethambutol, and N-geranyl-N’-(2-adamantyl)ethane-1,2-diamine (SQ109) on Mycobacterium 
tuberculosis H37Rv. J. Pharmacol. Exp. Ther. 315:905–911. 
179.  Reddy VM, Einck L, Andries K, Nacy CA. 2010. In vitro interactions between new 
antitubercular drug candidates SQ109 and TMC207. Antimicrob. Agents Chemother. 54:2840–2846. 




180.  Tahlan K, Wilson R, Kastrinsky DB, Arora K, Nair V, Fischer E, Barnes SW, Walker JR, 
Alland D, Barry CE 3rd, Boshoff HI. 2012. SQ109 targets MmpL3, a membrane transporter of 
trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium 
tuberculosis. Antimicrob. Agents Chemother. 56:1797–1809. 
181.  Yew WW, Chau CH, Wen KH. 2008. Linezolid in the treatment of “difficult” multidrug-
resistant tuberculosis. Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis. 12:345–346. 
182.  Schecter GF, Scott C, True L, Raftery A, Flood J, Mase S. 2010. Linezolid in the treatment of 
multidrug-resistant tuberculosis. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 50:49–55. 
183.  Migliori GB, Eker B, Richardson MD, Sotgiu G, Zellweger J-P, Skrahina A, Ortmann J, 
Girardi E, Hoffmann H, Besozzi G, Bevilacqua N, Kirsten D, Centis R, Lange C. 2009. A 
retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant 
tuberculosis. Eur. Respir. J. Off. J. Eur. Soc. Clin. Respir. Physiol. 34:387–393. 
184.  Alcalá L, Ruiz-Serrano MJ, Pérez-Fernández Turégano C, García De Viedma D, Díaz-
Infantes M, Marín-Arriaza M, Bouza E. 2003. In vitro activities of linezolid against clinical isolates of 
Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. 
Antimicrob. Agents Chemother. 47:416–417. 
185.  Alffenaar JWC, van der Laan T, Simons S, van der Werf TS, van de Kasteele PJ, de 
Neeling H, van Soolingen D. 2011. Susceptibility of clinical Mycobacterium tuberculosis isolates to a 
potentially less toxic derivate of linezolid, PNU-100480. Antimicrob. Agents Chemother. 55:1287–1289. 
186.  Hillemann D, Rusch-Gerdes S, Richter E. 2008. In Vitro-Selected Linezolid-Resistant 
Mycobacterium tuberculosis Mutants. Antimicrob. Agents Chemother. 52:800–801. 
187.  Huang T-S, Liu Y-C, Sy C-L, Chen Y-S, Tu H-Z, Chen B-C. 2008. In vitro activities of 
linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 
years. Antimicrob. Agents Chemother. 52:2226–2227. 
188.  Wallis RS, Jakubiec W, Kumar V, Bedarida G, Silvia A, Paige D, Zhu T, Mitton-Fry M, 
Ladutko L, Campbell S, Miller PF. 2011. Biomarker-assisted dose selection for safety and efficacy in 
early development of PNU-100480 for tuberculosis. Antimicrob. Agents Chemother. 55:567–574. 




189.  Williams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, Grosset JH, Nuermberger E. 2008. 
Promising Antituberculosis Activity of the Oxazolidinone PNU-100480 Relative to That of Linezolid in a 
Murine Model. Antimicrob. Agents Chemother. 53:1314–1319. 
190.  Zhang Y. 2005. The magic bullets and tuberculosis drug targets. Annu. Rev. Pharmacol. Toxicol. 
45:529–564. 
191.  Zhang Y, Post-Martens K, Denkin S. 2006. New drug candidates and therapeutic targets for 
tuberculosis therapy. Drug Discov. Today 11:21–27. 
192.  Barbachyn MR, Hutchinson DK, Brickner SJ, Cynamon MH, Kilburn JO, Klemens SP, 
Glickman SE, Grega KC, Hendges SK, Toops DS, Ford CW, Zurenko GE. 1996. Identification of a 
novel oxazolidinone (U-100480) with potent antimycobacterial activity. J. Med. Chem. 39:680–685. 
193.  Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, Tompkins NM, Rose JD, 
Reynolds RC, Orme IM. 2005. Preclinical testing of the nitroimidazopyran PA-824 for activity against 
Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother. 
49:2294–2301. 
194.  Nuermberger E, Rosenthal I, Tyagi S, Williams KN, Almeida D, Peloquin CA, Bishai WR, 
Grosset JH. 2006. Combination Chemotherapy with the Nitroimidazopyran PA-824 and First-Line Drugs 
in a Murine Model of Tuberculosis. Antimicrob. Agents Chemother. 50:2621–2625. 
195.  Nuermberger E, Tyagi S, Tasneen R, Williams KN, Almeida D, Rosenthal I, Grosset JH. 
2008. Powerful Bactericidal and Sterilizing Activity of a Regimen Containing PA-824, Moxifloxacin, and 
Pyrazinamide in a Murine Model of Tuberculosis. Antimicrob. Agents Chemother. 52:1522–1524. 
196.  Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, 
Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WR. 2000. A 
small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405:962–966. 
197.  Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, 
Shimokawa Y, Komatsu M. 2006. OPC-67683, a nitro-dihydro-imidazooxazole derivative with 
promising action against tuberculosis in vitro and in mice. PLoS Med. 3:e466. 
198.  Sasaki H, Haraguchi Y, Itotani M, Kuroda H, Hashizume H, Tomishige T, Kawasaki M, 
Matsumoto M, Komatsu M, Tsubouchi H. 2006. Synthesis and antituberculosis activity of a novel 
series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles. J. Med. Chem. 49:7854–7860. 




199.  Alangaden GJ, Lerner SA. 1997. The clinical use of fluoroquinolones for the treatment of 
mycobacterial diseases. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 25:1213–1221. 
200.  Aubry A, Pan X-S, Fisher LM, Jarlier V, Cambau E. 2004. Mycobacterium tuberculosis DNA 
gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob. 
Agents Chemother. 48:1281–1288. 
201.  Aubry A, Veziris N, Cambau E, Truffot-Pernot C, Jarlier V, Fisher LM. 2006. Novel gyrase 
mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: 
functional analysis of mutant enzymes. Antimicrob. Agents Chemother. 50:104–112. 
202.  Ginsburg AS, Grosset JH, Bishai WR. 2003. Fluoroquinolones, tuberculosis, and resistance. 
Lancet Infect. Dis. 3:432–442. 
203.  Hu Y, Coates ARM, Mitchison DA. 2003. Sterilizing activities of fluoroquinolones against 
rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47:653–
657. 
204.  Kam KM, Yip CW, Cheung TL, Tang HS, Leung OC, Chan MY. 2006. Stepwise decrease in 
moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: 
correlation with ofloxacin susceptibility. Microb. Drug Resist. Larchmt. N 12:7–11. 
205.  Kubendiran G, Paramasivan CN, Sulochana S, Mitchison DA. 2006. Moxifloxacin and 
gatifloxacin in an acid model of persistent Mycobacterium tuberculosis. J. Chemother. Florence Italy 
18:617–623. 
206.  Lu T, Drlica K. 2003. In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria 
when combined with anti-tuberculosis agents. J. Antimicrob. Chemother. 52:1025–1028. 
207.  Alvirez-Freites EJ, Carter JL, Cynamon MH. 2002. In Vitro and In Vivo Activities of 
Gatifloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46:1022–1025. 
208.  Cynamon M, Sklaney MR, Shoen C. 2007. Gatifloxacin in combination with rifampicin in a 
murine tuberculosis model. J. Antimicrob. Chemother. 60:429–432. 
209.  Huitric E, Verhasselt P, Koul A, Andries K, Hoffner S, Andersson DI. 2010. Rates and 
Mechanisms of Resistance Development in Mycobacterium tuberculosis to a Novel Diarylquinoline ATP 
Synthase Inhibitor. Antimicrob. Agents Chemother. 54:1022–1028. 




210.  Lounis N, Gevers T, Van Den Berg J, Andries K. 2008. Impact of the interaction of R207910 
with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob. Agents 
Chemother. 52:3568–3572. 
211.  Wallis RS, Jakubiec W, Mitton-Fry M, Ladutko L, Campbell S, Paige D, Silvia A, Miller 
PF. 2012. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 
(sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PloS One 7:e30479. 
212.  Protopopova M, Hanrahan C, Nikonenko B, Samala R, Chen P, Gearhart J, Einck L, Nacy 
CA. 2005. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 
1,2-ethylenediamines. J. Antimicrob. Chemother. 56:968–974. 
213.  Lalloo UG, Ambaram A. 2010. New antituberculous drugs in development. Curr. HIV/AIDS 
Rep. 7:143–151. 
214.  Nikonenko BV, Protopopova M, Samala R, Einck L, Nacy CA. 2007. Drug Therapy of 
Experimental Tuberculosis (TB): Improved Outcome by Combining SQ109, a New Diamine Antibiotic, 
with Existing TB Drugs. Antimicrob. Agents Chemother. 51:1563–1565. 
215.  Manjunatha U, Boshoff HI, Barry CE. 2009. The mechanism of action of PA-824. Commun. 
Integr. Biol. 2:215–218. 
216.  Singh R, Manjunatha U, Boshoff HIM, Ha YH, Niyomrattanakit P, Ledwidge R, Dowd CS, 
Lee IY, Kim P, Zhang L, Kang S, Keller TH, Jiricek J, Barry CE. 2008. PA-824 Kills Nonreplicating 
Mycobacterium tuberculosis by Intracellular NO Release. Science 322:1392–1395. 
217.  Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van 
Niekerk C, Everitt D, Winter H, Becker P, Mendel CM, Spigelman MK. 2012. 14-day bactericidal 
activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. 
Lancet 380:986–993. 
218.  Tasneen R, Li S-Y, Peloquin CA, Taylor D, Williams KN, Andries K, Mdluli KE, 
Nuermberger EL. 2011. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a 
murine model of tuberculosis. Antimicrob. Agents Chemother. 55:5485–5492. 
219.  Manjunatha U, Boshoff HI, Barry CE. 2009. The mechanism of action of PA-824: Novel 
insights from transcriptional profiling. Commun. Integr. Biol. 2:215–218. 




220.  Nuermberger E, Tyagi S, Williams KN, Rosenthal I, Bishai WR, Grosset JH. 2005. 
Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. 
Am. J. Respir. Crit. Care Med. 172:1452–1456. 
221.  Saliu OY, Crismale C, Schwander SK, Wallis RS. 2007. Bactericidal activity of OPC-67683 
against drug-tolerant Mycobacterium tuberculosis. J. Antimicrob. Chemother. 60:994–998. 
222.  Diacon AH, Dawson R, du Bois J, Narunsky K, Venter A, Donald PR, van Niekerk C, 
Erondu N, Ginsberg AM, Becker P, Spigelman MK. 2012. Phase II dose-ranging trial of the early 
bactericidal activity of PA-824. Antimicrob. Agents Chemother. 56:3027–3031. 
223.  Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. 2010. Global tuberculosis drug 
development pipeline: the need and the reality. Lancet 375:2100–2109. 
224.  Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman MK. 2009. Safety, 
Tolerability, and Pharmacokinetics of PA-824 in Healthy Subjects. Antimicrob. Agents Chemother. 
53:3720–3725. 
225.  Cynamon MH, Klemens SP, Sharpe CA, Chase S. 1999. Activities of Several Novel 
Oxazolidinones against Mycobacterium tuberculosis in a Murine Model. Antimicrob. Agents Chemother. 
43:1189–1191. 
226.  Keshavjee S, Farmer PE. 2012. Tuberculosis, Drug Resistance, and the History of Modern 
Medicine. N. Engl. J. Med. 367:931–936. 
227.  Condos R, Hadgiangelis N, Leibert E, Jacquette G, Harkin T, Rom WN. 2008. Case series 
report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest 134:187–192. 
228.  Richter E, Rüsch-Gerdes S, Hillemann D. 2007. First Linezolid-Resistant Clinical Isolates of 
Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 51:1534–1536. 
229.  Paramasivan CN, Sulochana S, Kubendiran G, Venkatesan P, Mitchison DA. 2005. 
Bactericidal Action of Gatifloxacin, Rifampin, and Isoniazid on Logarithmic- and Stationary-Phase 
Cultures of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49:627–631. 
230.  Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi 
V, Bharath S, Balasubramanian V. 2007. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin 
against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict 
in vivo efficacy. Antimicrob. Agents Chemother. 51:576–582. 




231.  Drlica K, Malik M. 2003. Fluoroquinolones: action and resistance. Curr. Top. Med. Chem. 
3:249–282. 
232.  Maxwell A. 1997. DNA gyrase as a drug target. Trends Microbiol. 5:102–109. 
233.  Shindikar AV, Viswanathan CL. 2005. Novel fluoroquinolones: design, synthesis, and in vivo 
activity in mice against Mycobacterium tuberculosis H37Rv. Bioorg. Med. Chem. Lett. 15:1803–1806. 
234.  Von Groll A, Martin A, Jureen P, Hoffner S, Vandamme P, Portaels F, Palomino JC, da 
Silva PA. 2009. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and 
gyrB. Antimicrob. Agents Chemother. 53:4498–4500. 
235.  Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. 1998. In vitro and in vivo 
activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob. Agents 
Chemother. 42:2066–2069. 
236.  Lounis N, Bentoucha A, Truffot-Pernot C, Ji B, O’Brien RJ, Vernon A, Roscigno G, 
Grosset J. 2001. Effectiveness of Once-Weekly Rifapentine and Moxifloxacin Regimens  against 
Mycobacterium tuberculosis in Mice. Antimicrob. Agents Chemother. 45:3482–3486. 
237.  MacGowan AP. 1999. Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. 
Expert Opin. Investig. Drugs 8:181–199. 
238.  Nuermberger EL, Yoshimatsu T, Tyagi S, O’Brien RJ, Vernon AN, Chaisson RE, Bishai 
WR, Grosset JH. 2004. Moxifloxacin-containing regimen greatly reduces time to culture conversion in 
murine tuberculosis. Am. J. Respir. Crit. Care Med. 169:421–426. 
239.  Cynamon MH, Sklaney M. 2003. Gatifloxacin and ethionamide as the foundation for therapy of 





































3.1 EXPRERIMENTAL STRATEGY  
Complementary strategies were used to determine the effect of the EPIs on anti-TB drugs in RIF resistant 
M. tuberculosis clinical isolates (Figure 3). 
 








3.2 STRAIN SELECTION   
Eight RIF mono-resistant M. tuberculosis clinical isolates were selected from an existing sample bank 
maintained at the Stellenbosch University, Western Cape, South Africa. Isolates from this sample bank 
were previously phenotypically and genotypically characterized. The selected isolates had different 
genetic backgrounds based on IS6110 RFLP fingerprinting and spoligotyping and were from the 
following families: Beijing (n= 4), LCC (n=1), F13 (n=1) and Haarlem (n=1). These clinical isolates  had 
identical rpoB531 (Ser-Leu) mutation with varying levels of RIF resistance, as determined in by MGIT 
(25) (PhD thesis, Gail E. Louw, 2009) (Table 3.1). In addition, the sensitive laboratory H37Rv 
ATCC27294 strain and a clinical isolate K636 were used as susceptible controls.  
Table 3.1: Genotypic and phenotypic characteristic of the selected RIF mono-resistant M. tuberculosis 
clinical isolates with rpoB531 (Ser-Leu) mutation. 
Family  Spoligotype pattern Spoligotype 
number 
























n= 8; LCC = Low Copy Clade; MIC = minimum inhibitory concentration 
 
3.3 CULTURE OF M.TUBERCULOSIS STRAINS  
M. tuberculosis isolates were cultured on Lowenstein-Jensen (LJ) solid media and incubated at 37⁰C for 
3-4 weeks with continuous aeration. Subsequently, colonies were scraped from the LJ slants and starter 
cultures were prepared by inoculating the colonies into 10 ml 7H9 Middlebrook medium (Becton, 
Dickinson Microbiology system, Sparks, USA), supplemented with 10 % albumin-dextrose-catalase 
(ADC), 0.2 % (v/v) glycerol (Merck Laboratories, Saarchem, Gauteng, SA) and 0.1 % Tween80 (Becton, 




Microbiology systems, Sparks, USA). Cultures were grown in filtered screw cap tissue culture flasks 
(Greiner Bio-one, Maybachstreet, Germany) without shaking and incubated at 37⁰C until an optical 
density (OD600) of 0.6 - 0.8 was reached. Contamination of these cultures was assessed by Ziehl-Neelsen 
(ZN) staining and culture on blood agar plates (APPPENDIX). Subsequently, 80% glycerol stock-cultures 
were prepared from uncontaminated starter cultures and stored at -80⁰C.  
3.4 GENOTYPIC CHARACTERISTICS OF CLINICAL ISOLATES 
The phenotypically confirmed RIF mono-resistant M. tuberculosis clinical isolates were characterized by 
PCR amplification and targeted gene sequencing to confirm the presence of the rpoB531 (Ser-Leu) 
mutation and the absence of other drug resistance conferring mutations.  
3.4.1 DNA extraction 
A volume of 500 µl of each strain, sub-cultured in MGIT vial supplemented with OADC (Becton, 
Dickinson and Company, Sparks, USA), was incubated at 100⁰C for 20-30 min. The extracted crude 
DNA was then stored at 4⁰C for subsequent analysis.  
3.4.2 Primers of TB drug resistance conferring genes for PCR amplification 
The primers (Table 3.2) used for PCR amplification and targeted gene sequencing were obtained from an 













Table 3.2: Primers used for the amplification of TB drug resistance conferring genes 
Anti-TB 
drugs 
Gene Primer Sequence (5-3’) Tm  (⁰C) Fragment 
length 


















55⁰C 246 bp 




62⁰C 615 bp 




















62⁰C 344 bp 
 
3.4.3 PCR amplification conditions and fragment visualisation 
The PCR master-mix comprised of 5µl 10X buffer (Qiagen), 1µl of MgCl2 (2.5 mM), 10 µl of Q-solution 
(Qiagen), 4 µl deoxyribonucleotide triphosphates (dNTP’s) (Promega) (0.2 mM of each dNTP), (0.25 µl 
of Forward primer (50pmol/µl) , 0.25 µl Reverse primer (50 pmol/µl) (of specific gene amplified), 0.15 µl 
Hotstar Taq polymerase (5 units/µl) (Qiagen). Subsequently, 2.5 µl of the crude DNA template was added 
to the PCR master mix. No template controls were included in each reaction to assess possible 
contamination. Additionally, DNA from the laboratory strain, H37Rv ATCC27294 was included as a 
positive control. The PCR reactions were carried out in the GeneAmp PCR System 2400 (Applied 
Biosystems, Foster City, CA, USA) and thermal cycling conditions were as follows: an initial denaturing 




step at 95⁰C for 15 minutes, followed by 45 cycles of denaturation at 94⁰C for 1 minute, annealing at the 
Tm of the specific gene primer (Table 3.2) for 1 minute, extension at 72⁰C for 1 minutes and final 
extension step at 72⁰C 15 minutes. Successful amplification of the amplified fragments were visualised on 
a 1.5% agarose gel, stained with ethidium bromide.  
3.4.5 DNA Sequencing and mutation detection 
The PCR products were submitted for PCR clean-up and sequencing at the Central Analytic Facility 
(CAF) of Stellenbosch University. Gene sequences were then aligned using DNA MAN Version 4.1 and 
the respective gene sequence of M. tuberculosis H37Rv reference strain 
(http://genolist.pasteur,fr/Tuberculist).  
3.5: COMPOUND SELECTION 
3.5.1 ANTI-TB DRUG: 
Ten anti-TB drugs were selected for this study based on their use in TB treatment (as defined by the 
WHO) and from different structural and functional classes. These anti-TB drugs included:  the 
fluoroquinolones (FQs) [OFL, MOXI, and CIP]; aminoglycosides [STR, AMI, and CAP (polypeptide)]; 
INH, ETH, EMB and PZA (Sigma-Aldrich Chemie, St Louis, USA). Drugs were dissolved in specific 
diluents according to the instructions by the manufacturers. The aminoglycosides (CAP, AMI and STR), 
INH, PZA and EMB were dissolved in sterile distilled water (dH2O), while the FQs (OFL, MOXI and 
CIP) were dissolved in 0.1% sodium hydroxide (NaOH) (Sigma-Aldrich Chemie, St Louis, USA). RIF 


















Table 3.3: Classification of different groups of anti-TB drugs  
Drug group Drug name 
 
Group 1 


















Group 4  





3.5.2 EFFLUX PUMP INHIBITORS: 
Three efflux pump inhibitors were selected based on their reported structural and functional properties. 
These efflux pump inhibitors included: Verapamil (calcium channel blocker) antagonist), Reserpine (an 
alkaloid) and carbonyl cyanide 3-chlorophenyldrazone (CCCP) (protonophore) (Sigma-Aldrich, St Louis, 
USA). Verapamil was dissolved in sterile dH2O, whereas reserpine and CCCP were dissolved in 100% 
DMSO (Merck KGaA, Darmstadt, Germany). The optimal concentration of verapamil was  previously 
determined as 40 µg/ml for anti-TB drugs resistant isolates and 10 µg/ml for pan-susceptible isolates (25). 
The optimal concentrations of CCCP and reserpine were determined in this study at concentrations 
ranging from 10 µg/ml to 80 µg/ml.  
3.6 DRUG MIC DETERMINATION 
3.6.1 Anti-TB drugs  
The MICs for the respective anti-TB drugs for the clinical isolates were determined in the BACTEC 
MGIT 960 instrument (BD Bioscience, MD, USA) according to the manufacturer instructions. The 
minimum inhibitory concentration (MIC) is defined as the lowest concentration of a antimicrobial 
compound needed to eliminate 99% of the bacterial cells in a culture (34). In order to determine the MICs 
for ten drugs (CAP, AMI, STR, MOXI, CIP, OFL, ETH, INH, PZA and EMB), dilutions of these drugs 




were made in small increments. The dilutions started at 2 x lower followed by 10 x lower than the critical 
concentration for the specific anti-TB drugs (Table 3.4). Sub-cultures were prepared by inoculating 200 μl 
of previously prepared M. tuberculosis stock-cultures in MGIT 960 media supplemented with 800 μl of 
OADC. These sub-cultures were then incubated at 37°C in the MGIT 960 instrument until a positive 
growth reading was obtained, which is typically a GU> 400. Two days after obtaining positive growth, 
the growth control tubes were prepared by inoculating 500 μl of the 1:100 diluted sub-cultures into 
OADC enriched MGIT tubes. 
Subsequently, 500 μl of the undiluted positive sub-cultures were inoculated into MGIT tubes enriched 
with 800μl OADC and 100 μl of the anti-TB drug specific drug concentrations (Table 3.4).The MGIT 
tubes were then registered on the EpiCenter (version 5.75A) TBeXist software (BD Bioscience, 
Erembodegem, Belgium) and placed in BACTEC MGIT 960 instrument to continuously monitor the 
growth for 14 consecutive days. PZA MIC determination was done under different conditions, due to 
PZA being active at pH 5.5 in vitro, thus influencing the growth of the mycobacteria. For this reason, 
PZA MIC testing was done in a PZA MGIT 960 kit was used as per manufacture’s instruction (35, 36) in 
modified MGIT 960 PZA medium (37).  
3.6.2 Efflux pump inhibitor 
3.6.2.1 EPI optimal concentration determination 
a) MGIT 960 
The optimal concentration of the EPI was defined as the highest concentration of drug that resulted in 
<10% growth inhibition. This was done in the MGIT 960 system and EpiCenter software as described 
above. The concentrations for the different efflux pump inhibitor used ranged from 10 µg/ml to 80 µg/ml 
(Table 3.4).   
b) Broth Micro dilution 
The preliminary findings from our group, demonstrated that reserpine influences the turbidity of the 
MGIT media, thus having a direct effect on determining the growth based on fluorescence (38).  For this 
reason, the non-inhibitory concentration of reserpine and its effect on the MICs of the anti-TB drugs were 
determined using the Broth Microdilution Method in a 96-well v-bottom plate (Greiner Bio-one, 
Maybachstreet, Germany). Briefly, M. tuberculosis isolates were grown to an OD600nm of 0.2- 0.3 (~106 
CFU/ml) and subsequently diluted 1:100 in 7H9 Middlebrook media. Subsequently, 100 µl 7H9 medium 




(drug free control) were pipeted in row 1 well 1, 1.6% DMSO (diluent) were pipetted in row 1 well 2, and 
reserpine (inhibitor) were pipetted in row 1 well 3-4 at 4 x the initial required concentration (Table 3.4). 
Afterwards, 50 µl of 7H9 medium was added to all wells from row 2- 12 and reserpine was serially 
diluted (2 fold) in the 96 well plates. Finally, 50 µl of the 1:100 diluted culture (~104 cells/well) was 
added to rows 2-12 and all was done in duplicates. The inoculated 96-well plates were placed in zip lock 
bags and incubated at 37⁰C for 7 to 14 days.  
3.6.2.2 EPI in combination with anti-TB drugs 
a) MGIT 960 system 
The effect of the EPI on the MIC of the anti-TB drugs were determined in the MGIT 960 system, based 
on the instructions of the manufacturer. Briefly, sub-cultures were prepared by inoculating 200 μl of 
previously prepared M. tuberculosis stock-cultures in MGIT 960 media supplemented with 800 μl of 
OADC. These sub-cultures were then incubated at 37°C in the MGIT 960 instrument until a positive 
growth reading was obtained. After two days of obtaining positive growth, the growth control tubes were 
prepared by inoculating 500 μl of the 1:100 diluted sub-cultures into OADC enriched MGIT tubes. 
Subsequently, 500 μl of the undiluted positive sub-cultures were inoculated into MGIT tubes enriched 
with 800μl OADC and 100 μl of each of the ten drugs (CAP, AMI, STR, MOXI, CIP, OFL, ETH, INH, 
PZA and EMB) separately in the presence of verapamil (40 µg/ml (resistant strains) and 10 µg/ml 
(sensitive strains). Additionally, in the presence of CCCP (7.5 µg/ml (resistant) and 4.0 µg/ml (sensitive) 
at determined MICs and 10-fold lower respectively. Moreover, verapamil and CCCP only controls were 
included to show that the EPI had minimal effect on the growth of the bacterial population. In addition 
drugs-only controls were included for all the anti-TB drugs tested to show and validate that the change in 
growth was due to the presence of verapamil and CCCP. Finally, the MGIT tubes were then registered on 
the Epicenter and placed in BACTEC MGIT 960 instrument to continuously monitor the growth for 14 
consecutive days. 
b) Broth Micro dilution  
The Broth Micro dilution (BMD) was used to determine the effect of reserpine on the MICs of the anti-
TB drugs as described in section 3.5 (EPI optimal concentration determination). This was done by 
incubating reserpine (80 µg/ml) in combination with the ten drugs (CAP, AMI, STR, MOXI, CIP, OFL, 
ETH, INH, PZA and EMB) at determined MICs. The reserpine-only control was included to show that 
the reserpine had minimal effect on the growth of the bacterial population, also a drug-only control for all 
the anti-TB drugs tested to show and validate that the change in MIC was due to the presence of 




reserpine. Further other controls included 7H9 medium and the drug diluents (1.6% DMSO and dH2O) as 
positive controls to show that the bacterial growth was independent of them. All experiments were done 
in triplicate for verification purposes. 
Table 3.4: Concentrations of anti-TB drugs used for MIC determination 
Anti-TB drug  Critical 
concentration  
(µg/ml)a 
MIC (µg/ml)b Range of 
concentrations tested 
Reference 
INH 0.1/0.4 0.02 -0.2  0.01- 0.4 (39–42) 
ETH 5.0/12.5 2.5 - 10 1.25 -12.5 (39–42) 
EMB 5.0 1 - 5 0.5- 5.0 (39–42) 
PZA 100 16 - 50 10- 100 (39–42) 
OFL 2.0 0.5 – 2.0 0.2- 2.0  (39–42) 
MOXI 0.25 0.18 - 0.2 0.025- 0.25 (43–45) 
CIP 1.0 0.5 0.1- 1.0  (41, 42) 
STR 1.0 < 1.0 0.1- 1.0  (39–42) 
AMI 1.0 < 1.0 0.1- 1.0 (41, 42) 
CAP 2.5 1.25 0.25- 2.5  (41, 42) 
Efflux pump 
inhibitor * 









Verapamil 25 – 50 5 - 50 10 - 40  (2, 25, 46–48) 
CCCP n/a 1 – 7.5 1.25- 15  (2, 46, 49) 
Reserpine n/a 80 1.25- 100 (25, 38, 46, 47) 




a) Critical concentration as defined by the WHO (41) The critical concentration (CC) was defined as the 
drug concentration that discriminates between drug sensitivity and resistance, as defined by the WHO; b) 
MIC that was reported in the literature ; c) EPIs typical active concentrations of the (concentration at 
which  do not inhibit growth); d) EPIs sub-inhibitory concentrations reported was reported in 
literature;*The EPIs active concentration ranges were obtained from literature searches and used as 
starting point to determine the final non-inhibitory concentrations used in the present study 
3.6.2.3 Interpretation of results 
a) MGIT 960/EpiCenter 
Results were read when the growth control reached a growth unit (GU) > 400. When a GU of the tested 
drug tube was ≥ 100, the isolate was interpreted as being resistant (R). In contrast the isolate was sensitive 
(S) if the GU of the tested drug tube was <100 and remained the same after being incubated for more 7 
days. The isolates was interpreted as intermediate (I) if the GU of the tested drug tube was > 100 during 7 
days after the growth control GU reached > 400 (38, 42). The same procedure was used to read the 
growth units of the EPI’s and drugs combination.  
b) Broth Micro dilution  
The plates were read by a visual inspection after 7 days of incubation to determine whether bacterial 
pellets have formed formation at the bottom of the plates.  If no bacterial pellets were visible, the plates 
we left for another 12-14 days.  On day 13 a blue resazurin reagent was added to the 96-well plate and left 
overnight at 37°C in the incubator (24 hrs). The blue non-fluorescent resazurin reagent is reduced to 
highly fluorescent resorufin by dehydrogenase enzymes in metabolically active cells. This conversion 
only occurs in viable cells and thus, the amount of resorufin produced is proportional to the number of 
viable cells in the sample. The conversion from resazurin to resorufin would result in a colour change 
from blue to pink, which represents bacterial growth (which was scored as either growth (+++), no 
growth (-) or partial growth (+/-) if less than 50% growth. 
3.7 STATISTICAL ANALYSIS 
3.7.1 ANOVA: F-test (STATISTICA VERSION 11)  
Descriptive statistics (ANOVA: F-test) was used to determine the significance of Verapamil or CCCP on 
the growth of M. tuberculosis, either alone or in combination with anti-TB drugs.   




3.7.2 Fractional inhibitory concentration formula index (FIC) 
The fractional inhibitory concentration (FIC) formula index was used, to assess the anti-TB 
drugs/inhibitor interactions. FIC formula index is an isobologram mathematical expression used to 
analyze the synergistic properties in drug/inhibitor combination experiments. The FIC is defined as a ratio 
of the MIC observed in an inhibitor/drug combination to the MIC of the same drug tested alone [Equation 
3.6] (50, 51). The FIC indices determination was done for all the EPIs (reserpine, verapamil and CCCP). 
In the case of veparamil and CCCP experiments which was done in the MGIT system, the FIC was 
defined as a ratio of the GU assessed in an inhibitor and drug combination to the GU of the same drug 
tested alone (Equation 3.7a). In addition, for reserpine experiments based on a BMD method, the FIC was 
defined as a ratio of the MIC assessed in an inhibitor and drug combination to the MIC of the same drug 
tested alone (Equation 3.7b). In addition, the interaction FIC indices were classified as follows: 
synergistic when FIC index ≤ 0.5-0.9, indifferent/additive when FIC index = 1-1.9 and antagonistic when 
FIC index ≥ 2FIC (50–53). 
Equation 3.7: FIC mathematical calculation used to assess drug/inhibitor interactions 
a)                                                                            
                   
 
and 
b)                                                                
                  









































4.1 THE GENOTYPIC CHARACTERISTICS OF CLINICAL ISOLATES 
Genotypic characterization identified the rpoB531 (Ser-Leu) mutation in the 8 RIF mono-resistant clinical 
M. tuberculosis isolates analysed. In contrast, no mutation was identified in the rifampicin resistant 
determining region (RRDR) rpoB gene for the clinical susceptible M. tuberculosis isolate (K636) or the 
H37Rv laboratory strain. Moreover, isolate R810 was found to harbour an inhA promoter mutation, 
therefore this isolate does not represent a RIF mono-resistant phenotype but an MDR phenotype. For this 
reason, this isolate was excluded from subsequent experiments (Appendix C).  
4.2 ANTI-TB DRUG MIC DETERMINATION 
4.2.1 Anti-TB drugs 
The MICs of the anti-TB drugs in RIF mono-resistant (n=7) and pan-susceptible isolates (n=2) were 
determined. Five out of seven RIF mono-resistant isolates with the same rpo531 mutation showed 
sensitivity at the critical concentration of the various drugs assessed (Table 4.1), confirming the RIF 
mono-resistant phenotype. However, two isolates (Haarlem and unclassified families) showed resistance 
at the critical concentration of PZA (100 µg/ml), thus suggesting a multiple resistance phenotype. 
Genotypic analysis of the pncA gene showed no mutations suggesting alternative resistance mechanisms 
conferring the PZA resistance phenotype. Both pan-susceptible strains (K636 and H37Rv) showed 













Table 4.1: The range of MICs for the different anti-TB drugs in the RIF mono-resistant clinical 
























RIF c 2.0  70-160 80 130 130 130 0.2- 0.5 
INH 0.1/0.4 0.03- 0.05 0.03 0.03 0.05 0.05 0.05- 0.2 
ETH 5.0/12.5 1.0 – 10.0 1.50 0.60 10.0 1.25 3.5 – 10.0 
EMB 5.0 1.5- 2.5 1.0 0.50 0.50 2.00 1.0 – 3.0 
PZA 100 50 50 100d 50 100d 22.5 -25 
OFL 2.0 0.20 0.20 0.20 0.20 0.20 0.25 – 0.50 
MOXI 0.25 0.04 0.04 0.06 0.04 0.04 0.06 – 0.13 
CIP 1.0 0.1- 0.25 0.10 0.10 0.10 0.25 0.13 – 0.25 
STR 1.0 0.07- 0.1 0.10 0.10 0.25 0.10 0.13 – 0.80 
AMI 1.0 0.1-0.25 0.25 0.25 0.25 0.25 0.25 – 0.50 
CAP 2.5 0.4 -0.6 0.60 0.60 0.60 0.60 1.00 – 1.25 
a) critical conc. of the anti-TB drugs in a MGIT (µg/ml) (41), b) number of isolates in specific family, c) 
previously determined by G. Louw et al (25) d) The MICs showing resistant at critical concentrations. 
4.2.2 Efflux pump inhibitor 
4.2.2.1Determined EPI optimal concentrations  
i) The optimal sub-Inhibitory concentration of CCCP. 
The optimal sub-inhibitory concentration of CCCP was determined to assess the highest concentration of 
efflux pump inhibitor where ≥ 90% of M. tuberculosis growth was observed.  
To determine the sub-inhibitory concentration of CCCP, clinical resistant isolates from the different strain 
families (LCC, Beijing and F13) were selected. The CCCP concentrations tested ranged from 5 to 15 
µg/ml for the resistant isolates and 2.5 to 5 µg/ml for the susceptible isolates (Table 4.2). From this assay 
it was determined that the sub-inhibitory optimal concentration for CCCP for the resistant and susceptible 
isolates were, 7.5 µg/ml and 4.0 µg/ml, respectively (Table 4.2).  
 




ii) The optimal sub-Inhibitory concentration of Reserpine 
Our group previously determined the optimal concentrations 40 and 80 µg/ml for the efflux pump 
inhibitors verapamil and reserpine respectively for the resistant isolates (25). For the susceptible isolates, 
it was previously determined to be 10 and 30 µg/ml for verapamil and reserpine, respectively (25) . The 
above assays were done by the BACTEC 460TB method. To assess the sub-inhibitory optimal 
concentration for reserpine in resistant isolates, by the Broth Microdilution Method, the concentrations 
tested ranged from 1280 µg/ml to 1.25 µg/ml. It was observed that 80 µg/ml reserpine was the optimal 
concentration, thus confirming previous findings (25).  
Table 4.2: The optimal sub- inhibitory concentrations of CCCP in clinical isolates 
 














 15 10 7.5 5 4.0 3.0 2.5 
LLC 0.0% 72.0 98.7%b 100% NDa ND ND 
BEIJING 0.0% 70.3% 92.1%b 95.0% ND ND ND 

















K636 ND ND ND 86.6% 90.9%b 92.1% 94.6% 
H37Rv ND ND ND 90.6% 95.0%b 96.4% 99.8% 
a) Concentration not done for the specific phenotypic group, b) the chosen sub-inhibitory concentrations 
for CCCP were at concentrations where ≥ 90% of the M. tuberculosis still grew. 
4.2.2.2 EPI in combination with anti-TB drugs 
a) MGIT 960 
i) The effect of verapamil on M. tuberculosis growth at the MICs of different anti-TB drugs  
Significant overall growth inhibition was observed (p = 0.0026, 95% confidence interval) when M. 
tuberculosis RIF resistant isolates were grown in the presence of a combination of verapamil (40 µg/ml) 
and the different anti-TB drugs relative to anti-TB drugs alone (Figure 4 A). This growth inhibition was 




specifically observed for RIF resistant isolates grown in the presence of the combination of verapamil (40 
µg/ml) and INH (0.03- 0.05 µg/ml), ETH (0.6 – 10.0 µg/ml), EMB (0.5 – 2.5 µg/ml), PZA (50 µg/ml), 
CIP (0.1 – 0.25 µg/ml), STR (0.07 – 0.25 µg/ml), AMI (0.1- 0.25 µg/ml) or CAP (0.4 – 0.6 µg/ml). This 
effect was independent of the genetic background of the studied isolates. In contrast, the addition of 
verapamil (40 µg/ml) significantly stimulated growth in the presence of OFL (0.2 µg/ml) MOXI (0.04 – 




































Figure 4 A: Growth of RIF resistant isolates in different anti-TB drugs in the presence or 
absence of verapamil (40 µg/ml).* denotes statistical significant difference; Descriptive 
statistics (ANOVA: F-test) plot: LS means, current effect: F (9, 52) = 4.4080, p= 0.0026, Type III 
decomposition; vertical bars denotes 95% confidence intervals (the mean growth units obtained 
for the different RIF resistant isolates tested). RIF resistant isolates were cultured in the presence 
of ETH (0.6 – 10.0 µg/ml), PZA (50 µg/ml), STR (0.07 – 0.25 µg/ml), AMI (0.1- 0.25 µg/ml), 
CAP (0.4 – 0.6 µg/ml), INH (0.03- 0.05 µg/ml), EMB (0.5 – 2.5 µg/ml), CIP (0.1 – 0.25 µg/ml), 
OFL (0.2 µg/ml) or MOXI (0.04 – 0.06 µg/ml). 
 
Verapamil (10 µg/ml) did not significantly alter the growth of the drug susceptible M. tuberculosis 
isolates (p= 0.5464; 95% confidence interval) when cultured in the presence of INH (0.05- 0.2 µg/ml), 
ETH (3.5 – 10.0 µg/ml), PZA (22.5- 25 µg/ml), CIP (0.13 – 0.25 µg/ml), STR (0.13 – 0.8 µg/ml), AMI or 




(0.25- 0.5 µg/ml) (Figure 4 B). However, a significant decrease in growth was observed for these isolates 
grown in the presence of verapamil (10 µg/ml) and EMB (1.0-3.0 µg/ml), MOXI (0.06 – 0.13 µg/ml) or 
OFL (0.25-0.5 µg/ml) while an increased in growth was observed in the presence of verapamil and CAP 






























Figure 4 B: Growth of RIF susceptible isolates cultured in the presence of different anti-TB 
drugs and in the presence or absence of verapamil (10 µg/ml).* denotes statistical significant 
difference; Descriptive statistics (ANOVA: F-test) plot: LS means, F (9, 9) = 0.92318, p= 0.5464, 
Type III decomposition; vertical bars denotes 95% confidence intervals (the mean growth units 
obtained for the different RIF resistant isolates tested). RIF susceptible isolates were cultured in 
ETH (3.5 – 10.0 µg/ml), PZA (22.5 - 25 µg/ml), STREP (0.1 – 0.8 µg/ml), AMI (0.25- 0.5 
µg/ml), CAP (1.0 – 1.25 µg/ml), INH (0.05 – 0.2 µg/ml), EMB (1.0 – 3.0 µg/ml), OFL (0.25 – 
0.5 µg/ml), MOXI (0.06 - 0.13 µg/ml) or CIP (0.13 – 0.25 µg/ml).  
 
Further analysis of the effect of structurally related and unrelated compounds in combination with 
verapmil showed that the structurally related anti-TB drugs (OFL, MOXI and CIP) behave similarly to 
one another but differently to those that are not structurally related (STR, AMI and CAP), (INH, ETH) or 
EMB and PZA (Figure 4 C).  
 





















Figure 4 C: Graphic representation of the similarities and differences in growth of RIF 
resistant isolates when cultured in the presence of structural analogs and structurally 
unrelated anti-TB drugs together with verapamil. Descriptive statistics (ANOVA: F-test) plot: 
LS means, current effect: F (9, 52) = 4.4080, p= 0.0026, Type III decomposition; vertical bars 
denotes 95% confidence intervals. Overlapping of the letters abcdef shown in the graph 
represents the similar and different behavior of anti-TB drugs in the presence of verapamil. If the 
anti-TB drugs in the graph show similar letters, they behave similarly. However, if they show 
different letters, they behave differently. 
ii) The effect of CCCP on M. tuberculosis growth at the MICs of different anti-TB drugs  
The addition of CCCP (7.5 µg/ml) had a significantly overall growth inhibition (p = 0.01196, 95% 
confidence interval) on the growth of RIF resistant isolates cultured in the presence of different anti-TB 
drugs (Figure 4 D). This synergy was specifically observed for resistant isolates grown in the presence of 
CCCP (7.5 µg/ml) and INH (0.03 – 0.05 µg/ml), PZA (50 µg/ml or CAP (0.4 – 0.6 µg/ml) TB drugs. 
Moreover, indifference/addative was observed for resistant isolates grown in the presence of CCCP (7.5 
µg/ml) and ETH (0.6 – 10.0 µg/ml), MOXI (0.04 – 0.06 µg/ml), EMB (0.5 – 2.5 µg/ml) or STR (0.07 – 
0.25 µg/ml). However, the presence of CCCP (7.5 µg/ml) had an antagonistic effect when OFL (0.2 
µg/ml), CIP (0.1 – 0.25 µg/ml) or AMI (0.1- 0.25 µg/ml) were present in the medium. The influence of 
CCCP on growth was independent of the genetic background of the studied isolates. 
 














































Figure 4 D: Growth RIF resistant isolates cultured in the presence of different anti-TB 
drugs and in the presence or absence of CCCP (7.5 µg/ml). * denotes statistical significant 
difference; Descriptive statistics (ANOVA: F-test) plot: LS means, current effect: F (9, 52) = 1, 
7771, p= 0.01196; vertical bars denotes 95% confidence intervals (the mean growth units 
obtained for the different RIF resistant isolates tested). RIF resistant isolates were cultured in the 
presence of (ETH (0.6 – 10.0 µg/ml), PZA (50 µg/ml), STR (0.07 – 0.25 µg/ml), CAP (0.4 – 0.6 
µg/ml), INH (0.03- 0.05 µg/ml), EMB (0.5 – 2.5 µg/ml), MOXI (0.04 – 0.06 µg/ml), OFL (0.2 
µg/ml), CIP (0.1 – 0.25 µg/ml) or AMI (0.1- 0.25 µg/ml). 
 
In contrast, CCCP (4.0 µg/ml) did not significantly alter the growth of the sensitive M. tuberculosis 
isolates (p = 0.5085, 95% confidence interval) when cultured in the presence of certain anti-TB drugs 
(Figure 4 E). However, a significant decrease in growth was observed for these isolates when grown in 
the presence of CCCP (4.0 µg/ml) and EMB (1.0 – 3.0 µg/ml) µg/ml) or PZA (22.5 - 25 µg/ml). 
 





























Figure 4 E: Growth of RIF susceptible isolates cultured in the presence of different anti-TB 
drugs and in the absence and presence of CCCP (4.0 µg/ml).* denotes statistical significant 
difference; Descriptive statistics (ANOVA: F-test) plot: LS means, F (9, 9) = 0.98548, p= 
0.50851, Type III decomposition; vertical bars denotes 95% confidence intervals (the mean 
growth units obtained for the different RIF resistant isolates tested). RIF susceptible isolates were 
cultured in the presence of ETH (3.5 – 10.0 µg/ml), PZA (22.5 - 25 µg/ml), STR (0.1 – 0.8 
µg/ml), CAP (1.0 – 1.25 µg/ml) INH (0.05 – 0.2 µg/ml), EMB (1.0 – 3.0 µg/ml), OFL (0.25 – 0.5 
µg/ml), MOXI (0.06 - 0.13 µg/ml) or AMI (0.25- 0.5 µg/ml). 
 
Further analysis of the effect of structurally related and unrelated compounds in combination with CCCP 
showed that; the structurally related anti-TB drugs either (OFL, MOXI and CIP), (STR, AMI and CAP), 
(INH, ETH) or EMB and PZA behave similarly to one another but differently to those that are not 
structurally related (Figure 4 F). The same observation was seen as per verapamil. 
It was observed that the analogs INH, ETH have a similar effect on the growth of M. tuberculosis strains 
in combination with CCCP (Figure 4F). This is expected as they are structural analogs and share common 
gene targets. Furthermore, a similar observation was seen for MOXI and CIP with slight difference for 
OFL. Interestingly, the latter anti-TB drugs are all FQs and with the same mechanism of action (inhibit 
DNA replication). Nevertheless, different behavior was observed to other structurally unrelated (STR, 
AMI and CAP), (INH, ETH) or EMB and PZA.  
 























Figure 4 F: Graphic representation of the similarities and differences in growth of RIF 
resistant isolates when cultured in the presence of structural analogs and structurally 
unrelated anti-TB drugs together with CCCP. Descriptive statistics (ANOVA: F-test) plot: LS 
means, current effect: F (9, 52) = 1, 7771, p= 0.01196; vertical bars denotes 95% confidence 
intervals. Overlapping of the letters abc shown in the graph represents the similar and different 
behavior of anti-TB drugs in the presence of verapamil. If the anti-TB drugs in the graph show 
similar letters, they behave similarly. However, if they show different letters, they behave 
differently. 
 
iii) The effect of verapamil on M. tuberculosis growth at the critical conc. of RIF (2.0  µg/ml)  
The effect of verapamil (40 µg/ml) on the growth of RIF resistant isolates cultured in the presence of RIF 
(2.0 µg/ml) was determined. From figure 4G it is evident that verapamil (40 µg/ml) significantly 
enhanced the growth of the RIF resistant isolates in the presence or absence of RIF (2.0 µg/ml) (p = 
0.0001, 0.95 CI). This effect was independent of the genetic background of the studied isolates. 
Conversely, verapamil (10 µg/ml) did not significantly (p= 0.0048) alter the growth of the pan-susceptible 
isolates in the presence of RIF (2.0 µg/ml) and this was done in duplicates. 
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Figure 4 G: Growth of RIF resistant isolates. Descriptive statistics (ANOVA: F-test) 
plot: LS means, current effect: F (10, 98) = 10.231, p= 0.0001, Type III decomposition; 
vertical bars denotes 95% confidence intervals (the model is based on the data from all of 
the isolates tested). RIF resistant isolates were cultured in the presence of RIF (2.0 
µg/ml), verapamil (40 µg/ml) or RIF (2.0 µg/ml) and verapamil (40 µg/ml) and this was 












 2 RIF + 10 VP

























Figure 4 H: Growth of pan-susceptible isolates. Descriptive statistics (ANOVA: F-test) 
plot: LS means, current effect: F (14, 14) = 4.3296, p= 0.0048, Type III decomposition; 
vertical bars denotes 95% confidence intervals (the model is based on the data from all of 
the isolates tested). Pan-susceptible isolates were cultured in the presence of RIF (2.0 
µg/ml), verapamil (10 µg/ml) or RIF (2.0 µg/ml) and verapamil (10 µg/ml) and this was 
done in duplicates.   
 
iv) The effect of CCCP on M. tuberculosis growth at the critical concentration of RIF (2.0 µg/ml). 
The effect of CCCP (7.5 µg/ml) on the growth of RIF resistant isolates cultured in the presence of RIF 
(2.0 µg/ml) was determined. From, Figure 4I it is evident that CCCP (7.5 µg/ml) significantly enhanced 
the growth of the RIF resistant isolates in the presence or absence of RIF (2.0 µg/ml) (p= 0.0001, 0.95 
CI). Moreover, it was shown to increase the lag phase and this effect was independent of the genetic 
background of the studied isolates. Conversely, CCCP did not significantly (p > 0.05) alter the growth of 
the pan-susceptible isolates in the presence of RIF (2.0 µg/ml) as expected (data not shown).and this was 
done in duplicates.  
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Figure 4 I: Growth of RIF resistant isolates. Descriptive statistics (ANOVA: F-test) plot: LS 
means, current effect: F (18, 54) = 3.7098, p= 0.0001, Type III decomposition; vertical bars 
denotes 95% confidence intervals (the model is based on the data from all of the isolates tested). 
RIF resistant isolates were cultured in the presence of RIF (2.0 µg/ml), CCCP (7.5 µg/ml) or RIF 
(2.0 µg/ml) and CCCP (7.5 µg/ml) and this was done in duplicates. 
 
b) Broth Microdilution Method 
i) The effect of reserpine on the growth M. tuberculosis cultured in the presence of different anti-TB drug.  
The inclusion of reserpine (80 µg/ml) in the culture media had a significant influence on the MICs of 
some tested anti-TB drugs in the RIF resistant isolates. This was reflected by observed different MICs 
fold changes (2-6 folds) in the presence of reserpine and INH, ETH, MOXI, CIP, STR, AMI, CAP, EMB 
and PZA respectively (Table 4.3). In contrast, reserpine did not influence the OFL MIC significantly 
(Table 4.3).The inclusion of reserpine (30 µg/ml) in the culture media did not alter the MICs of the 
sensitive M. tuberculosis (H37Rv) laboratory strain for some of the anti-TB drugs (Table 4.3). However, 
the presence of reserpine (30 µg/ml) significantly decreased the MIC for INH (6-fold), EMB (4-fold), and 
OFL, MOXI, CIP, STR and CAP by 2-fold (Table 4.3).  
 
 




Table 4.3: Effect of reserpine on the MICs of different anti-TB drugs (MIC fold changes) as measured 
using different RIF resistant and susceptible isolates. 
Clinical isolates  R 160  R 637  R 376 H37Rv 
Drug  MIC (µg/ml) up-fold changes in the presence of reserpine 
INH  4 2 6 6 
ETH  0 0 4 0 
EMB  2 4 0 4 
PZA  0 2 0 0 
OFL  0 0 0 2 
MOXI  2 4 2 2 
CIP  4 4 0 2 
STR  2 2 4 2 
AMI  2 2 2 0 
CAP  2 0 0 2 
 
ii) The effect of reserpine at the critical concentration of RIF (2.0 µg/ml). 
The influence of reserpine (80 µg/ml) on the MIC for RIF was determined in the panel of RIF resistant M. 
tuberculosis isolates. The findings from the present showed that reserpine caused a drastic increase in the 
RIF MIC (2.0 – 32 µg/ml) (10-fold increase). However, the inclusion of reserpine (30 µg/ml) did not 
influence the RIF MIC of the drug sensitive M. tuberculosis (H37Rv) laboratory strain (Table 4.4). 
 
 




Table 4.4 The influence of reserpine on the RIF critical conc. for RIF resistant and susceptible isolates. 








Drug treatment RIF critical conc. (µg/ml)  
RIF 2.0 2.0 2.0 0.5 
RIF+reserpine 32 32 32 0.5 
MIC fold change 10 10 10 0 
a) Denotes tested RIF resistant isolates b) Denotes tested RIF susceptible isolate 
4.3 The synergistic properties of EPIs and anti-TB drugs MICs combination 
The fractional inhibitory concentrations (FIC) of RIF resistant isolates were calculated to assess the 
interaction of verapamil (40 µg/ml), CCCP (7.5 µg/ml) or reserpine (80 µg/ml) with the different anti-TB 
drugs MICs. The FIC indices were classified as follows: synergistic when FIC index ≤ 0.5-0.9, 
indifference/additive when FIC index = 1-1.9 and antagonistic when FIC index ≥ 2FIC (25,26). Different 
equations were used to calculate the FIC indices because two different technologies used (MGIT 960 and 
Broth Microdilution). For verapamil (40 µg/ml) and CCCP (7.5 µg/ml) Equation 3.6A with growth units 
was used, while for reserpine (80 µg/ml) Equation 3.6B with MIC valued was used (chapter 3). The FIC 
indices for verapamil (40 µg/ml) and CCCP (7.5 µg/ml) are tabulated in Table 4.5 and for reserpine (80 
µg/ml) interaction tabulated in Table 4.6.  
Based on the calculated FIC indices, synergistic interaction was observed in the presence of verapamil (40 
µg/ml) or CCCP (7.5 µg/ml) in combination with INH, ETH, PZA and CAP (Table 4.5). Conversely, 
indifference interaction was observed in combination with EMB, MOXI and OFL. Additionally, 
synergistic interaction was observed in the presence of verapamil (40 µg/ml) but indifference interaction 
in the presence of CCCP (7.5 µg/ml) in combination with STR, AMI and CIP. Moreover, synergistic 
interaction was observed in the presence of reserpine (80 µg/ml) in combination with INH, STR and AMI 
in all clinical isolates (Table 4.6). However, for other anti-TB drugs (CAP, PZA, EMB, CIP, MOXI, ETH 










Table 4.5: FIC indices for verapamil and CCCP in combination with different anti-TB drug as 







CCCP (FIC)  Inhibitor/drug 
interaction  
INH  0.5 synergistic  0.4  synergistic  
ETH  0.2 synergistic  0.9  synergistic  
EMB  1.3  indifference  1.5  indifference  
PZA  0.6 synergistic  0.3 synergistic  
OFL  1.1  indifference  1.6  indifference  
MOXI  1.0  indifference  1.1  indifference  
CIP  0.8  synergistic  1.7  indifference 
STR  0.4 synergistic  1.2  indifference  
AMI  0.7 synergistic  1.7  indifference  










Table 4.6: FIC indices for reserpine in combination with different anti-TB drug as determined in different 















INH  0.2 synergistic 0.5 synergistic 0.1 synergistic 
ETH  2 antagonistic 2 antagonistic 0.3 synergistic 
EMB  0.5 synergistic 0.3 synergistic 2 antagonistic 
PZA  1 indifference 0.5 synergistic 1 indifference 
OFL  1 indifference 1 indifference 1 indifference 
MOXI  0.5 synergistic 0.3 synergistic 2 antagonistic 
CIP  0.3 synergistic 0.2 synergistic 1 indifference 
STR  0.5 synergistic 0.5 synergistic 0.3 synergistic 
AMI  0.5 synergistic 0.5 synergistic 0.5 synergistic 








































Central dogma suggests that mutations in target genes are the main cause of drug resistance in M. 
tuberculosis (3, 9–11, 54). In addition, previous studies report that efflux related mechanisms may 
contribute to intrinsic resistance and to the process whereby drug resistance is acquired (2, 5, 25, 28, 32, 
38, 55, 56). Furthermore, recent studies have shown that efflux mechanisms may impact on the level of 
resistance following the mutation in defined target genes (rpoB and gyrA) (25, 57). This phenomenon has 
been shown by an increase in susceptibility to anti-TB drugs in the presence of efflux pump inhibitors (2, 
5, 21, 28, 58–60). In this study, we aimed to test the hypothesis that the addition of efflux pump inhibitors 
could synergize with first- and second-line anti-TB drugs to enhance their bacteriocidal/bacteriostatic 
effect. Enhancing the activity of current anti-TB drugs could significantly shorten treatment thereby 
easing the management of TB patients and decreasing the risk of default. 
In this study, all of the isolates tested exhibited a susceptible phenotype when cultured at the critical 
concentration for INH, ETH, EMB, PZA, OFL, MOXI, OFL, STR, AMI and CAP. However, two isolates 
showed resistance towards PZA implying multiple resistance and were subsequently excluded from 
further analysis. The remaining clinical isolates showed minor variations in their level of intrinsic 
resistance to the respective anti-TB drugs. This variation in the level of intrinsic resistance is commonly 
observed and forms the basis for defining the critical concentration used to differentiate between 
susceptible and resistant phenotypes (41). Previous studies have suggested that genetic background may 
define the level of intrinsic resistance (25, 61); however we were unable to demonstrate an association 
between the level of intrinsic resistance and the genetic background of the strains tested given the small 
number of strains tested.  
Our study showed that the addition of the efflux pump inhibitor Verapamil, decreased bacterial growth in 
the presence of INH, ETH, PZA, CIP, STR, AMI or CAP suggesting an increased susceptibility towards 
these drugs. This implies that the addition of the efflux pump inhibitor blocked the active transport of 
these molecules out of the cell leading to the intracellular accumulation of these drugs and thereby 
enhancing their inhibitory effect. Conversely, verapamil increased resistance to OFX and MOX, as 
measured by the observed increased growth, suggesting that verapamil inhibited the uptake of these 
drugs. Together these results demonstrate the involvement of MFS and ABC superfamilies efflux pumps 
in defining the level of intrinsic resistance to the various anti-TB drugs. Similarly, by depriving energy 
that drives efflux through inhibition of the proton transport chain with CCCP we showed that 
susceptibility toward INH, ETH, PZA and CAP could be restored. However, reserpine resulted in restored 
susceptibility towards INH, STR and AMI in all three RIF mono-resistant strains tested. Together this 




implies that different classes of efflux pumps may be involved in defining the level of intrinsic resistance 
to specific drugs. These observations were not restricted to RIF mono-resistant isolates suggesting that 
efflux is also involved in defining the level of intrinsic resistance. However, these results are not directly 
comparable given that the concentrations of efflux pump inhibitors used were significantly lower for the 
susceptible strains. 
Our results were in concordance with previous findings that suggested that high-level INH resistance was 
mainly driven by efflux when RIF mono-resistant clinical isolates were exposed to the combination of 
INH and verapamil or chlorpromazine (60). The authors also noted that exposure of RIF mono-resistant 
strains to INH significantly increased expression of mmpL7, P55, efpA, Rv1258c, Rv2459 and mmr genes, 
as well as inhibited in the presence of verapamil or chlorpromazine. Based on our findings, we suggest 
that INH is extruded by members of the MFS, ABC and RND efflux pump families which are inhibited 
by CCCP, verapamil and reserpine. This is supported by a previous study which showed that iniA 
(membrane protein) extruded INH and that reserpine blocked this efflux mechanism (6, 63, 64). 
Additionally, the overexpression of inhA induce efflux of INH (65) and this was reversed by CCCP, 
verapamil and reserpine. In the current study, we observed that susceptibility towards ETH was also 
significantly increased in the presence of CCCP, and verapamil (synergy observed). This is in agreement 
with previous reports which have shown that CCCP inhibits P55-dependent drug resistance to ETH and 
other anti-TB drugs in M. tuberculosis (27, 66, 67). The P55-efflux pump (MFS superfamily) utilizes the 
electrochemical and transmembrane proton gradients as source of energy (6, 20, 67) which is targeted by 
CCCP.  
Interestingly, our data also showed that verapamil and reserpine increased susceptibility towards the 
aminoglycosides STR and AMI in RIF mono-resistant clinical isolates. In addition, CCCP increased 
susceptibility towards CAP. This suggests that the aminoglycosides and cyclic peptides are extruded 
multiple efflux pumps (ABC, RND and MFS superfamilies). These findings may aid in the development 
of novel inhibitors to target these efflux pump targets and thereby improve/strengthen MDR-TB treatment 
regimens.  
The present study revealed that reserpine reduced the MIC for EMB by 2-4 fold, suggesting synergy. 
Conversely, verapamil and CCCP showed indifference in their effect on EMB, suggesting that efflux of 
EMB was restricted to a define group of efflux pump inhibitors. This was supported by a study by Gupta 
et al. who reported that an increase in the expression of jefA increased EMB and INH resistance in M. 
tuberculosis by MFS superfamily efflux pumps and the this resistance could be reversed with the addition 
of reserpine (58).  




Our findings contrast with previous studies (2, 25, 68) concerning the synergy of efflux pump inhibitor 
and fluoroquinolone susceptibility. This in part could be explained by differences in the genetic 
backgrounds of the strains tested, extent of resistance and the concentration of the inhibitors used. Our 
results also conflicted with a previous finding which showed that the addition of verapamil and reserpine 
enhanced susceptibility to RIF in RIF resistant clinical isolates of M. tuberculosis (25, 28). Interestingly, 
we observed an increase in mycobacterial growth in the presence of verapamil suggesting that this 
inhibitor prevents RIF from entering the cell thereby increasing resistance to RIF. In concordance with 
previous studies we showed that CCCP increased susceptibility to RIF (2.0 µg/ml), suggesting the 
involvement of MFS, ABC and RND class/group of efflux pumps. A similar effect was not observed for 
RIF susceptible isolates confirming the absence of efflux defining the level of intrinsic resistance (2, 69). 
This suggests that the RIF mono-resistant clinical isolates have adapted mechanisms to survive 
environmental stresses of RIF.  
Based on the overall findings of the present study, we propose a model: “Inhibition of efflux = restored 
anti-TB drug susceptibility”. The model demonstrates that the inhibition of efflux pumps contributes to 
the decrease in intrinsic resistance. Moreover, intrinsic resistance results when efflux pumps are activated 
and decrease intracellular drug concentration (Figure 5: Senerio A). This mechanism is driven by the 
efflux pump inhibitors that inhibit the activity of efflux pump (Figure 5: Senerio B), thereby resulting 
restored susceptibility to the efflux pump substrates (anti-TB drugs).   
The clinical explanation of the presented model suggest that treating a RIF resistant strain with first and 
second line anti-TB drugs, might stimulate overexpression of the bacterial ABC, MFS and RND 
superfamilies. This would result in the up-regulation of encoded efflux pump genes to extrude the various 
anti-TB drugs. In return, the intracellular anti-TB drug concentration decreases thereby the concentration 
is not sufficient to cause a killing response. The addition of verapamil, CCCP and reserpine blocks the 
efflux pumps, leading to an increase in the intracellular drug concentration. This results in the anti-TB 










PROPOSED A MODEL: INHIBITION OF EFFLUX = RESTORED ANTI-TB DRUG SUSCEPTIBILITY 
Figure 5: Diagrammatic illustration of “Inhibition of efflux = restored anti-TB drug susceptibility”; the inhibition of EPs responsible for 
intrinsic resistance by use of EPIs, results in restored susceptibility to extruded anti-TB drugs (substrate to the EP). 































The current study provided evidence that an efflux related mechanism contributes to the level of intrinsic 
drug resistance in RIF mono-resistant M. tuberculosis clinical isolates with an rpoB531 (Ser-Leu) 
mutation. The MICs to the various drugs were confirmed to be sensitive at the respective critical 
concentrations, with the exception of PZA. The variable intrinsic resistance of the RIF mono-resistant 
isolates was independent of the genetic background. This could be explained by the technical challenges 
of phenotypic PZA testing and alternative resistance mechanisms. This study showed that PZA resistance 
could be reversed with the addition of efflux pump inhibitors, thus supporting previous findings.    
 We observed that combination therapy with EPIs, first and second line anti-TB drugs had a significant 
inhibitory effect on the growth of M. tuberculosis isolates. This suggests that the addition of verapamil, 
CCCP and reserpine plays a significant role in restoring the susceptibility (change in MIC and decrease in 
intrinsic resistance level) of the RIF mono-resistant isolates to these anti-TB drugs. A synergistic effect 
was also observed by the combination treatment of the anti-TB drugs with the different efflux pump 
inhibitors.  These findings have clinical implications as combination treatment with EPI and anti-TB 
drugs could improve MDR-TB therapy outcome. The proposed model is based on the data obtained from 
this study and by incorporating evidence from the literature. We proposed that suggests that the 
overexpression of EPs in the clinical isolates studied, results in the up-regulation of encoded EP genes 
followed by the extrusion of multiple anti-TB drugs out of the cell. This decrease in intracellular drug 
accumulation results in decreased drug-target affinity, thus causing multidrug resistance. Additionally, the 
use of EPIs can inhibit active efflux and increase anti-TB drug concentration. 
Reserpine and verapamil were observed to be the most potent efflux pump inhibitor, with CCCP being the 
least effective.  These findings (i) provided a proof of principle for the synergistic effect of drugs and EPI 
combination in MDR-TB treatment (ii) emphasized the need to design novel compounds which will also 
target EPs and reduce spread of drug resistance and tolerance. An example is SQ109 which targets 
MmpL3 involved in mycolic acid, the disruption of cell wall assembly and TMC207 which showed 
significant synergistic effect when combined with PZA and TMC207 (chapter 2) and both are currently in 
clinical trials.  
In summary, based our the findings and published literature, the present study confirms what was 
suggested by other studies, namely that efflux pumps play a crucial role in the level of intrinsic resistance. 
However, this is the first to investigate the effect of different efflux pumps on the level of intrinsic 
resistance to a broad spectrum of anti-TB drugs (first- and second-line) in drug resistant M. tuberculosis 
clinical isolates from different genetic backgrounds. Even more important, the present study also showed 




that the variation in the level of intrinsic resistance is independent of the genetic background. Thus, this 
also emphasizes that drug resistance is more complex than previously thought. 
A limitation in the present study is the lack of efflux pump gene expression analysis. However, future 
work would entail investigating the gene expression of the different efflux pumps in RIF mono-resistant 
M. tuberculosis clinical isolates by quantitative real-time polymerase chain reaction (qRT-PCR). This 
assessment would identify the specific efflux pump genes (individual or combination) that might aid in 
the extrusion of the various structurally related/unrelated anti-TB drugs. Functional studies on the 
different efflux pump genes would also provide evidence of the extent to which a specific gene contribute 
to intrinsic drug resistance. As, only few in vivo studies have been reported in this topic; this include 
Mooy J et al study that showed reduction in the bioavailability of the calcium antagonist in patients 
treated for 6 month with verapmil in combination with RIF, EMB and INH. Additionally, G. Louw et al 
study in BALB/c mice showed that treatment with verapamil in combination with first-line drugs 
significantly reduces pulmonary CFUs after 1 and 2 months. Hence, the correlation of the in vitro 
combination therapy data to in vivo studies would be informative. This would provide data that might be 
of clinical significance. In short, in-depth knowledge of efflux /inhibitor mechanisms in correlation with 
anti-TB drug resistance will help in the design and development of novel drugs/ inhibitors therapy and 
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APPENDIX A: BIO-SAFETY LEVEL III (P3) LABORATORY 
Good microbiological laboratory practices 
The risk of being infected with M. tuberculosis pathogen is high for personnel who work in laboratory 
that handle live M. tuberculosis processing. Hence the P3 laboratory was designed with specific 
engineering controls, administrative procedures and appropriate personal work practices that will ensure 
the organism containment and protection of the workers. The P3 laboratory is a facility used to facilitate 
safety when working with the Class III pathogens. Furthermore the facility is made up of main laboratory 
area which can be accessed through an access controlled airlock system. To ensure that the air from inside 
the P3 laboratory doesn’t escape to the entire building, the negative pressure is controlled throughout the 
laboratory. 
To comply with section 43 of the Occupational Health and Safety Act for dealing with hazardous 
biological agents (esp. M. tuberculosis) regulations: before personnel could be allowed to work in P3, had 
to undergo a complete medical examination to ensure personnel vaccinated and fit to work in P3. Then 
the safety training was done by safety officer and after the personnel was provided with the access code 
together with a safety manual on how to handle M. tuberculosis cultures when working in P3. 
P3 laboratory: Good laboratory Practice administered when working with of live M. tuberculosis 
Protective clothing was worn prior working in P3 laboratory, these included impervious quality long 
sleeves wrap-around gown, nitrile cloves, overshoes and masks for safety purposes when working with 
M. tuberculosis. 
All M. tuberculosis culturing was prepared aseptically in biological safety cabinets (BSC) and the BSC 
was disinfected as follows: 
 Firstly 10% incidin was prepared and used to decontaminate the BSC hood work surface, then 
sprayed and wiped with 70 % ethanol also to completely disinfect the BSC hood working surface. In 
addition this was done daily when processing cultures in order to avoid the use of old incidin.  
 Secondly all equipments used, reagents and cultures were also sprayed and wiped with 70% ethanol 
before entered in BSC hood; then wiped with 10% incidin before taken out of the BSC hood. 
 All waste materials were double bagged into autoclave plastic bags and autoclaved at 121⁰C for30 
minutes before being disposed. 




 Moreover after handling infectious M. tuberculosis cultures, gloves were removed and hands were 
washed with disinfectant soap in P3 working area, then gown was removed in P3 changing room and 
washed the hands again before leaving P3 laboratory. 
 The BSCs were serviced and certified by a trained external contractor for every six months. Also the 
pressure gauge and airflow in these cabinets were maintained daily prior starting work in order to 
ensure that the BSC is operating at optimum level. 
 Lastly all the procedures were carried out discreetly, without overcrowding the cabinet, keeping the 
air intake and exhaust grilles free to minimize any formation of splashes or aerosols.  
 
APPENDIX B: REAGENTS, MEDIA AND SOLUTIONS 
 
CULTIVATION OF M.TUBERCULOSIS STRAINS 
7H9 Liquid medium: 
4.7 7H9 Middlebrook medium 
0.5 Tween 80 
2 ml glycerol 
900 ml dH2O 
Autoclave at 121⁰C for 15 minutes 
Enrich with 100 ml OADC/ADC 
 
7H10 Middlebrook Agar Medium: 
19 g of 7H10 agar powder  
900 ml dH2O 
5 ml glycerol 
Boil for 1 min and autoclave at 121⁰C for 10 min 
Enrich with 100 ml OADC (at cooled temperature of 50 - 55⁰C) 
 
GEL ELECTROPHORESIS 
10 X TBE Buffer: 
108 g of 0.45M Tris 
55 g of 0.44M boric acid 
7.4 g of 10mM EDTA  




 1 L dH2O 
 
1X TBE Buffer: 
100 ml of 10X TBE 




 8.5 g NaCl  
1L dH2O 
Tween saline: 
8.5 g NaCl 
0.10 g Tween 80 




2 g of NaOH 
500 ml dH2O 
 
0.02 % Resazurin NaCL: 
10 ml of the resazurin powder 
50 ml of dH2O 
 
DRUGS CONCENTRATIONS 
Ofloxacin, Moxifloxacin and Ciprofloxacin: 
80 mg of drug powder each in 0.1M NaOH 
Streptomycin, Capreomycin, Amikacin, Ethambutol and Isoniazid: 
80 mg of drug powder each in 10 ml dH2O 
Ethionamide and Rifampicin: 
80 mg of drug powder each in 10% (RIF) and 100% (ETH) DMSO 
Pyrazinamide: 
20 000 µg in 2.5 ml dH2O 
 




EFFLUX PUMP INHIBITORS CONCENTRATIONS 
Verapamil: 
80 mg of inhibitor powder in 10 ml dH2O 
Reserpine and CCCP: 
80 mg of inhibitor powder each in 10 ml DMSO 
BLOOD AGAR PLATES AND ZN STAINING  
The blood agar and ZN staining were done to monitor possible contamination. These included plating M. 
tuberculosis cultures onto blood agar for period of two days as M. tuberculosis does not grow on blood 
agar for that period. Secondly, ZN staining was done as follows. The smear cultures were prepared and 
heat fixed at 100⁰C for 2 hours. then they were stained with carbol-fuchsin (Becton, Dickinson and 
Company, Maryland, USA), followed by decolorizing them with acid alcohol and finally counterstaining 
them with methylene blue (Becton, Dickinson and Company, Maryland, USA). The counterstained 
smears were visualized at 100x (oil immersion) magnification under the microscope for acid-fast bacilli. 
As M. tuberculosis is an acid-fast bacilli which retain dyes when handled and heated with acid containing 
compounds, the bacilli were expected to appear pink. 
GEL ELECTROPHORESIS 
An agarose gel (1.5 %) was prepared by dissolving 1.5 g agarose (Sigma-Aldrich Chemie, St Louis, 
USA) in 100 ml 1X Tris/Borate/EDTA (TBE) buffer. After the solution was boiled in a microwave oven 
for 2-3 minutes, 5 µl of ethidium bromide was added to it. The agarose was poured into the gel rack and 
left for 30 minutes to solidify. Subsequently the PCR products were mixed with an equal volume (5 µl) of 
loading dye (0.25 % Xylene Cyanol, 30% glycerol) and loaded onto the gel. The gel was run at 160 V for 
1hours in 1X TBE Buffer. The gel was visualized under ultra violet light using the Kodak, Digital Science 









BACTEC MGIT 960 SYSTEM AND EPICENTER, (VERSION 5.75A) TBEXIST SOFTWARE 
OPERATION 
The BACTEC MGTI 960 is a complete automated system. It utilizes a fluorescence-quenching-based 
oxygen sensor to detect growth in combination with EpiCenter software fitted with the TB eXiST module 
(42, 70). This system was used to determine the MICs of the selected drugs and the effect of verapamil 
and CCCP on MICs of these drugs in RIF mono-resistant M. tuberculosis clinical isolates as 
recommended by the manufacturer. The MGIT 960 system comprised of the supplement kit which 
included the Mycobacteria Growth Indicator fluorescence Tubes (MGIT) containing 7 ml of modified 
Middlebrook 7H9 Broth base; Oleic acid, Albumin, Dextrose and Catalase (OADC) enrichment (71) and 
the MGIT instrument (Becton, Dickinson and Company, Sparks, MD, USA); which monitors the growth 
of cultivated M. tuberculosis strains. Subsequently, the data generated by the MGIT 960 instrument was 
analysed on the EpiCenter, (version 5.75A) TBeXist software (BD Bioscience, Erembodegem, Belgium).  
The MGIT tubes were entered into the MGIT instrument and incubated at 37°C and the fluorescence 
reading were captured every 60 min. In addition,  the analysis of the fluorescence readings were used to 
determine whether the tube  showed positive growth and thereby determine whether the sample tested 
contained viable organisms (72). According to the manufacturer, an instrument positive tube had to 
contain about 105 to 106 colony forming units per milliliter (CFU/ml). In addition, the culture vials which 
remained negative for minimum of 42 days (up to 56 days) showing no clear signs of positivity were 













BROTH MICRODILUTION METHOD 
 
Figure B: demonstration how the 96- well drug containing plate is prepared for MIC and non inhibitory 
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Diluent  Media 100 uL 
Strain 1 Strain 2 
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prev. row  
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APPENDIX C: SUPPLEMENTARY RESULTS DATA 
THE GENOTYPIC CHARACTERISTICS OF CLINICAL ISOLATE 
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wt wt wt wt wt wt wt wt wt wt 
R376 130 
wt wt wt wt wt wt wt wt wt wt 
R637 160 
wt wt wt wt wt wt wt wt wt wt 
R721 70 






wt wt wt wt 0wt wt wt wt 
R966 120 
wt wt wt wt wt wt wt wt wt wt 
R1035 130 
wt wt wt wt wt wt wt wt wt wt 
R458 130 







wt wt wt wt wt wt wt wt wt wt 
H37Rv 0.5 
wt wt wt wt wt wt wt wt wt wt 




MGIT RESULT EXAMPLE FROM EPICENTER TB EXIST FOR AN ISOLATE 
Below it’s a typical result from the raw data obtained from EpiCenter TB eXIST for isolate R1035, as an 
example describing how MIC results are interpreted. These firstly includes the TB eXIST worklist 
(Figure 3.5.1) which shows the MICs of three anti-TB drugs; ethionamide at 2.5 µg/ml (resistant [R]); 
0.25 µg/ml (R represented by undefined 3.1) and 0.625 µg/ml (R represented by undefined 3.2). Then 
ofloxacin at 2.0 µg/ml (Sensitive [S]); 1.0 µg/ml (S); 0.5 µg/ml (S) and last Ciprofloxacin at 1.0 µg/ml (S 
represented by undefined 2.1); 0.5 µg/ml (S represented by undefined 2.2) and 0.25 µg/ml (S represented 
by undefined 2.3). Secondly includes MGIT 960 TB eXIST graph plot (Figure 3.5.2). This shows the 
MIC plots for Ethionamide (where the GUs ≥ 100 for all tested concentrations); for both ofloxacin and 
ciprofloxacin (where the GUs = 0 at all concentrations). 
Figure C1: Illustration of TB eXIST Worklist MICs raw data result for isolate R1035 as an example.* denotes 
that GC: reached 400 and confirms the interpretation of the tested anti-TB drugs MIC wordlist results 
* 





Figure C2: MGIT 960 TB eXIST plot MICs raw data result for isolate R1035.* the blue line plot 





←GC: reached 400* 




BROTH MICRODILUTION RESULTS 
To to determine whether reserpine change the MICs of various anti-TB drugs in studied clinical isolates , 
the following conditions were assessed: the conversion of resazurin to resorufin by resulting in a colour 
change from blue to pink, this representrd bacterial growth and was scored as either growth (+++), no 
growth (-) or partial growth (+/-) if less than 50% growth. 
Table B: Representation of reserpine inhibitory effect (MIC changes) at the MICs of different anti-TB 
drugs in M. tuberculosis isolates* 
Clinical isolates R 160 R 637 R 376 H37Rv 
Drug treatment Anti-TB drugs MIC (µg/ml) in absence/presence reserpine  
INH 0.05 0.05 0.05 0.4 
INH+Reserpine 0.01 0.03 0.006 0.05 
ETH 1.5 1 0.6 3.5 
ETH +Reserpine 3 2 0.15 3.5 
EMB 2.5 2.5 0.5 1 
EMB +Reserpine 1.25 0.63 1 0.25 
PZA 150 50 200 22.5 
PZA + Reserpine 150 25 200 22.5 
OFL 0.2 0.2 0.2 0.5 
OFL +Reserpine 0.2 0.2 0.2 0.25 
MOXI 0.04 0.04 0.06 0.13 
MOXI +Reserpine 0.02 0.01 0.12 0.07 
CIP 0.1 0.25 0.1 0.25 
CIP+ Reserpine 0.03 0.06 0.1 0.13 
STR 0.1 0.1 0.1 0.8 
STR +Reserpine 0.05 0.05 0.03 0.1 
AMI 0.25 0.25 0.5 0.5 
AMI +Reserpine 0.13 0.13 0.25 0.5 
CAP 0.6 0.6 0.6 1.25 
CAP +Reserpine 0.3 0.6 0.6 0.625 
*the table demonstrates the change in MIC levels of various anti-TB drugs in the presence of reserpine in 
RIF mono-resistant clinical M. tuberculosis isolates and susceptible isolates.  
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